TWI282368B - Antibody for detecting mycoplasma pneumoniae - Google Patents

Antibody for detecting mycoplasma pneumoniae Download PDF

Info

Publication number
TWI282368B
TWI282368B TW090101940A TW90101940A TWI282368B TW I282368 B TWI282368 B TW I282368B TW 090101940 A TW090101940 A TW 090101940A TW 90101940 A TW90101940 A TW 90101940A TW I282368 B TWI282368 B TW I282368B
Authority
TW
Taiwan
Prior art keywords
antibody
protein
ribosomal protein
microorganism
pneumoniae
Prior art date
Application number
TW090101940A
Other languages
Chinese (zh)
Inventor
Takashi Etoh
Monzur Rahman
Original Assignee
Asahi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Corp filed Critical Asahi Kasei Corp
Application granted granted Critical
Publication of TWI282368B publication Critical patent/TWI282368B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56927Chlamydia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1253Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56933Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A method of specifically, quickly and highly sensitively detecting a microorganism belonging to Mycoplasma pneumoniae; an antibody to be used in the detection; a detection reagent kit; and a process for producing the antibody to be used in the detection. Namely, an antibody against the ribosomal protein of a microorganism belonging to Mycoplasma pneumoniae which reacts specifically with this microorganism; a method of detecting this microorganism in a specimen by using this antibody; and a detection reaction kit containing this antibody. The ribosomal protein is exemplified by Ribosomal Protein L7/L12 employed in detecting the infection with a microorganism causative of pneumonia.

Description

1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(1 ) 本發明係有關檢測一般肺炎起因微生物之肺炎黴漿菌 (Mycoplasma pneumoniae)所屬之微生物有效之抗體,該微生 物之檢測方法,該微生物之檢測用試藥k i t ,以及檢測 該微生物用抗體之製造方法者。 本發明係醫藥品業界,特別肺炎黴漿菌所引起之非定 型肺炎之診斷上爲極重要者,於醫藥產業上爲極有用者。 本發明係有效用於檢測含於由檢體,如:焊縫棉棒, 組織樣品,體液,實驗用溶液及培養物所採取檢體中之微 生物,肺炎黴漿菌者。 先行技術中,微生物感染症之診斷係藉由一般感染部 位等之原因菌檢測,或針對血淸,體液中之原因菌檢測抗 體後被確定者。特別是,此診斷其原因菌之檢測意味著可 迅速給予患者進行治療之極重要者。 檢測感染症原因菌通常經過原因菌之分離培養後,被 分類成依其生理學性,生化學性或結構特性爲基準將此進 行同定之培養同定法,使原因菌基因進行聚合酶鏈反應( P C R )法,或特異性核酸混合體之後使增幅後,檢測此之 基因診斷法以及抗體與原因菌之抗原標識相互特異反應被 利用後檢測原因菌之免疫學方法者。 惟,利用培養同定法或基因診斷法時,取得結果所需 時間極長。因此,以可於短時間內,且高感度檢測原因菌 者,迅速且適度治療患者有關之免疫學方法之其診斷被廣 泛使用之。 藉由先行免疫學方法之檢測感染症原因菌中,依不同 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)-4 - (請先閲讀背面之注意事? 果寫本頁) -裝·1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Office Employees' Consumption Cooperatives Printed V. Description of the Invention (1) The present invention relates to an antibody effective for detecting microorganisms belonging to Mycoplasma pneumoniae, which is a microorganism of general pneumonia, and a method for detecting the microorganism The test kit for detecting the microorganism, and the method for detecting the antibody for the microorganism. The present invention is extremely important for the diagnosis of non-type pneumonia caused by the pneumococcal bacteria in the pharmaceutical industry, and is extremely useful in the pharmaceutical industry. The invention is effective for detecting microorganisms, pneumococcal bacteria contained in samples taken from specimens such as: welded cotton swabs, tissue samples, body fluids, experimental solutions and cultures. In the prior art, the diagnosis of a microbial infection is detected by a cause of infection in a general infectious part or the like, or is determined after blood stasis, the cause of the bacteria in the body fluid is detected. In particular, the detection of the cause of the diagnosis means that it is extremely important for the patient to be treated promptly. Detection of infectious agents The bacteria are usually classified and cultured according to their physiological, biochemical or structural characteristics, and the same bacteria are subjected to polymerase chain reaction. After the PCR method or the specific nucleic acid mixture is used for amplification, the genetic diagnosis method and the immunological method for detecting the cause of the bacteria are detected by using the genetic diagnosis method and the antigen-identification of the antibody and the causative bacteria. However, when using the same method or genetic diagnosis method, it takes a long time to obtain results. Therefore, the diagnosis of immunological methods related to rapid and appropriate treatment of patients with short-term and high-sensitivity detection causes is widely used. In the case of the detection of infectious diseases by the prior immunological method, the Chinese National Standard (CNS) A4 specification (210X297 mm)-4 - (Please read the back of the note first? Write this page) - loaded ·

、tT 1282368 A7,tT 1282368 A7

經濟部智慧財產局員工消費合作社印製 五、發明説明(2 菌種各種標識抗原與抗體之組合被使用之。 肺炎黴漿菌係肺炎,支氣管炎及咽喉炎之一般原因菌 者。類似小真菌之格蘭氏陰性菌者,選擇性侵入人體體內 ,進而發病。一般社會上集團發症之肺炎約1 5〜2 〇% ’以及被限定集團內肺炎之5 0 %爲止可說是藉由肺炎黴 漿囷所引起者(Ragnar Norrby 1999)。 此菌爲極細小之不易培養的微生物者,於濃厚培養基 中形成小菌落。於營養富化瓊脂培養基中,肺炎黴獎菌之 成長極爲緩慢,於培養基中使菌體進行同定爲止至少需要 2 1天(0^1^1:〇,?〇6,61&1.1 980)。於人體體內具有幾種源 起黴漿菌種之微生物引起相同之生化學反應。另外,由於 沒有細胞壁,明亮顯微鏡下之觀察更爲不易(Knudson and MacLeod 1 979)。因做爲迅速檢測病原菌之診斷法者,並不 適用格蘭氏染色法與培養法等者。 檢測肺炎黴漿菌之基因配列所使用之D N A混合體分 析檢測係依取11^11等,;61^]^等及86]:1^1;等(^11^11,丫〇26¥61 al. 1 987; Bernet, Garret et al. 1 993; Buck, O'Hara et al. 1 9 9 3)等所報告者。檢測肺炎黴漿菌R i b 〇 s o m a 1 R N A ( r R N A )所使用之檢測,係被載於T i 11 ο n等(T i 11 ο n,D i a s e t al. 1980),Yogev 等(Yogev,Halachmi et al. 1 988),Gobel 等 (Gebel,Geiser et al· 1 987),Zivin 與 Monahan( EP〇 30 5145 )及 Gobeland 與 Stanbridge( E P 〇 2 5 0 6 6 2 )等者。Kai 等(Kai,Kamiya et al. 1987)及 Jensen 等(Jensen,Sondergard et al· 1993)等係記載肺 (請先閱讀背面之注意事Ϊ -JT. π寫本頁) •裝· -線· 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 5 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(3 ) 炎黴漿菌之1 6 S r R N A配列之啓發劑者。其中所述 全檢測係針對肺炎黴漿菌之D N A,或肺炎黴漿菌與 Mycoplasma genitalium之D N A所設計者。此等之檢測感度 較高,因此,極符合最近可利用之技術,如:利用p C R 法收集此等者。P C R法其感度非常高,且比起混合體可 以更短時間進行之。惟,培養肺炎黴漿菌陰性呈無症狀者 ,病癒後顯示攜帶者呈陽性,偶有擬陽性問題存在。 特開昭6 3 — 2 9 8號公報記載針對約431α1〇(1α1ΐ〇η之 肺炎黴獎菌之膜抗原蛋白質以使用monoclonal抗體之濕式 標繪法做爲基礎之免疫檢測法。惟,該抗體及使用該抗體 之檢測法對於特異性低之肺炎黴漿菌其種特異診斷不足而 產生問題點。更藉由此診斷法欲取得結果所需時間至少5 小時爲極大問題點者(M a d s e n e t a 1. 1 9 8 8)。 本發明係爲解決上述課題者。亦即,本發明係以提供 具特異性,且高感度下迅速檢測肺炎黴漿菌所屬之微生物 的方法,其檢測所使用之檢測用抗體,檢測用試藥k i t 爲目的者。本發明更以提供製造其檢測所使用之檢測用抗 體的方法爲目的者。 本發明者發現於所有微生物中保存同一機能之蛋白質 可做爲有效之抗原蛋白質。一般可預見的,此蛋白質之結 構變北極小。更有驚人之發現係針對該蛋白質之抗體爲特 異之微生物種或屬者,針對該蛋白質之抗體可利用特異性 微生物之種或屬的識別具多樣性之同時針對做爲對象之微 生物可檢測出其所有血淸型態。更詳細者係該蛋白質經過 (請先閲讀背面之注意事_ 5寫本頁) •裝. -線 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)_ 6 - 1282368 A7 ___ B7 __ 五、發明説明(4 ) 胺基酸配列變化後,同種間之結構完全相同,種爲相異時 則伴隨結構變化顯示種特異性之有用蛋白質者。 本發明者針對所有微生物細胞中做爲相同功能之分子 存在後,且,其胺基酸結構於微生物間具某程度之相異點 的細胞內分子,特別是一種核糖核蛋白體蛋白質之 Ribosomal Protein L7/L12蛋白質做爲討論重點。公知者 Ribosomal Protein (核糖體)L7/L12蛋白質爲分子量約13 kilodalton之蛋白質者,做爲必須核糖核蛋白體蛋白質存在 於蛋白質合成者。特別是針對含肺炎黴漿菌幾許微生物中 之Ribosomal Protein (核糖體)L7/L12蛋白質之總胺基酸配 列進行解析。 本發明者重視該分子即使相互微生物類似而其部份仍 具各微生物固有之結構部份,發現利用抗體針對此肺炎黴 獎菌之Ribosomal Protein (核糖體)L7/L12蛋白質可檢測各 種微生物,細菌之種特異,且,所有同菌種內之血淸型者 本發明者發現肺炎黴漿菌可於該蛋白質中取得特異性 抗體,以及利用該抗體可檢測肺炎黴漿菌之特異性,進而 完成本發明。 本發明發現肺炎黴漿菌對於Rib〇s〇mal Protein (核糖體) L7/L12蛋白質具特異性monoclonal抗體而被開發之。此抗 體爲新穎者,與先行公知之抗體不同,具有與該蛋白質特 異之反應性質者。 配列表中配列號碼1及2爲肺炎黴漿菌之Ribosomal 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事4 %寫本頁) 經濟部智慧財產局員工消費合作社印製 1282368 A7 B7 五、發明説明(5 ) Protein (核糖體)L7/L12基因之D N A配列及所對應之胺基 酸配列者(NCBI database accession #NC 000912)。又,配列 表所載之胺基酸配列之左端及右端分別爲胺基末端(以下 稱N末端)及羧基末端(以下,稱c末端)者,又,鹽基配 列之左端及右端分別爲5 末端及3 >末端者。交叉分型 之胺基酸配列之胺基酸代表1文字之略記者。又,於交叉 分型之中「+」之記號代表不同胺基酸而其疏水性等性質 類似之胺基酸者,「」之空白記號代表性質完全不同之胺 基酸者。且,本發明所述之基因操作一連串之分子生物學 上之貫驗藉由一般貫驗書所記載之方法進行者即可。做爲 該一般實驗書者例如:Molecular Cloning, A Uboratory manual,Cold spring Harbor Laboratory Press, Shambrook, J. 等( 1 989)者。 表1 交叉分型試驗 Μρ ·· 1 MAKLDKNQX.IESLKEMTrM£XDEIIKXV££AFGVSATPWAA6AVGGTQEAASEVTVKVT 60 1 M KLDK QUESLKEMTI+EIOEIIKAVEEAFGV^ATP+VAAGA g tqeaasev+vkvt Mg: 1 MGKLDKKQLIESLKEMTIVEIDEIIKAVEEATGVTATPIVAAGAASATQEAASSVSVKVT 60 (請先閲讀背面之注意事 :寫本頁) -裝· 訂 -線 經 濟 部 智 慧 財 產 局 消 費 合 作 社 印 Μρ: 61 GYTDNAKLAVLKLYREIAGVGLMEAKTAVEKLPCWKQDIKPEEXEELKKRFVEVGATVE 120 GY DNAKLAVLKLYREI GVGLMEAKTAVEKLPCWKQDXKPEEAEELKKHFVEVGArVE Mg: 61 GYADNAKLAVLKLYREITGVGLMEXKTAVEKLPCWKQDIKPEEAEELKKRFVEVGATVE 120Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printing 5, invention description (2 strains of various combinations of antigens and antibodies are used. Pneumococcal pneumonia, bronchitis and pharyngitis, the general cause of bacteria. Similar to small fungi The gram-negative bacteria selectively invade the human body and cause disease. In general, the group's pneumonia caused by the group is about 15~2 〇%' and the 50% of the pneumonia in the limited group can be said to be caused by pneumonia. Caused by moldy sputum (Ragnar Norrby 1999). This bacterium is a very small microbe that is difficult to culture. It forms small colonies in a thick medium. In the nutrient-enriched agar medium, the growth of Pneumococcal bacteria is extremely slow. At least 21 days (0^1^1: 〇, 〇6, 61 & 1.1 980) is required to make the cells in the culture medium. There are several microorganisms originating from the moldy species in the human body causing the same life. Chemical reactions. In addition, because there is no cell wall, observation under a bright microscope is more difficult (Knudson and MacLeod 1 979). Because it is a diagnostic method for rapid detection of pathogens, it is not suitable for Gram. Dyeing method, culture method, etc. The DNA mixture analysis and detection method for detecting the gene arrangement of Pythium oxysporum is based on 11^11, etc.; 61^]^ and 86]:1^1; etc. ^11,丫〇26¥61 al. 1 987; Bernet, Garret et al. 1 993; Buck, O'Hara et al. 1 9 9 3) Reported by the tester. Detection of Pneumoniae R ib 〇soma 1 The detection used for RNA (r RNA) is contained in T i 11 ο n et al (T i 11 ο n, D iaset al. 1980), Yogev et al (Yogev, Halachmi et al. 1 988), Gobel et al ( Gebel, Geiser et al. 1 987), Zivin and Monahan (EP〇30 5145) and Gobeland and Stanbridge (EP 〇2 5 0 6 6 2), etc. Kai et al. (Kai, Kamiya et al. 1987) and Jensen et al. (Jensen, Sondergard et al. 1993) and other departments record the lungs (please read the note on the back - JT. π write this page) • Install · - Line · This paper scale applies to China National Standard (CNS) A4 specification (210X297 5) 2 1282368 A7 B7 Ministry of Economic Affairs, Intellectual Property Bureau, Staff Consumer Cooperatives, Printing 5, Inventions (3) Inflammatory agents of 1 6 S r RNA. The whole test system is designed for D N A of P. oxysporum, or D N A of Mycoplasma pneumoniae and Mycoplasma genitalium. These detections are highly sensitive and therefore highly compliant with recently available technologies such as the collection of such methods using the p C R method. The P C R method has a very high sensitivity and can be carried out in a shorter time than the mixture. However, the culture of pneumococcal negative was asymptomatic, and the carrier showed positive after the illness, and occasionally the problem of quasi-positive. JP-A-63-209 discloses an immunoassay based on a wet-labeling method using a monoclonal antibody for a membrane antigen protein of 431α1〇 (1α1ΐ〇η P. pneumoniae). The antibody and the detection method using the same have a problem in that the specific diagnosis of the Pseudomonas pneumoniae with low specificity is insufficient, and the time required for the diagnosis to obtain the result is at least 5 hours, which is a great problem (M adseneta) 1. 1 9 8 8) The present invention is to solve the above problems. That is, the present invention provides a method for rapidly detecting microorganisms belonging to Pythium oxysporum with high specificity and high sensitivity. The antibody for detection and the reagent kit for detection are intended. The present invention further provides a method for producing a test antibody for use in the test. The present inventors have found that a protein having the same function can be effectively used in all microorganisms. The antigenic protein. It is generally foreseeable that the structure of this protein becomes a little Arctic. It is even more surprising that the antibody against the protein is a specific microbial species or genus. The antibody against the protein can be identified by the species or genus of the specific microorganism, and the microorganisms can be detected for all the blood sputum types. The more detailed is the protein passage (please read the back first) Note _ 5 write this page) • Install. - Line paper size applies to China National Standard (CNS) A4 size (210X297 mm) _ 6 - 1282368 A7 ___ B7 __ V. Description of invention (4) Amino acid arrangement After the change, the structure of the same species is completely the same, and when the species is different, the species-specific useful protein is accompanied by the structural change. The present inventors have a molecule which functions as the same function in all microbial cells, and an amine group thereof The Ribosomal Protein L7/L12 protein with an acid structure at a certain degree of difference between microorganisms, especially a Ribosomal Protein L7/L12 protein of ribonucleoprotein protein, is the focus of discussion. The Ribosomal Protein L7/L12 protein is known. A protein with a molecular weight of about 13 kilodalton, as a necessary ribonucleoprotein protein present in protein synthesizers. The total amino acid sequence of the Ribosomal Protein L7/L12 protein in several microorganisms was analyzed. The inventors of the present invention paid attention to the fact that even if the molecules are similar to each other, the part still has the structural part inherent to each microorganism, and it is found that the antibody is utilized. The Ribosomal Protein L7/L12 protein against the P. pneumoniae can detect various microorganisms, the species of the bacteria are specific, and all the bloody types in the same species, the inventors found that Pneumocystis may be The present invention has been accomplished by obtaining a specific antibody in a protein and detecting the specificity of M. pneumoniae using the antibody. The present inventors have found that M. pneumoniae has been developed for the specific monoclonal antibody of the Rib〇s〇mal Protein (ribosomal) L7/L12 protein. This antibody is novel and, unlike the previously known antibodies, has a specific reaction property to the protein. The number 1 and 2 in the matching list is Ribosomal of Pythium oxysporum. The paper size applies to the Chinese National Standard (CNS) A4 specification (210X297 mm). (Please read the note on the back first. 4% write this page) Ministry of Economics Intellectual Property Bureau employee consumption cooperative printed 1282368 A7 B7 V. Description of invention (5) Protein (ribosomal) L7/L12 gene DNA arrangement and corresponding amino acid ligand (NCBI database accession #NC 000912). Further, the left and right ends of the amino acid arrangement listed in the list are respectively an amine terminal (hereinafter referred to as an N terminal) and a carboxyl terminal (hereinafter referred to as a c terminal), and the left and right ends of the salt base are respectively 5 End and 3 > end. Cross-typed amino acid-matched amino acids represent a one-word reporter. Further, in the cross-type, the symbol "+" represents a different amino acid and its hydrophobicity is similar to that of an amino acid. The blank mark of "" represents an amino acid of a completely different nature. Further, a series of molecular biological tests performed by the present invention can be carried out by the methods described in the general test. As a general experimenter, for example, Molecular Cloning, A Uboratory manual, Cold spring Harbor Laboratory Press, Shambrook, J. et al. (1 989). Table 1 Cross-type test Μρ·· 1 MAKLDKNQX.IESLKEMTrM£XDEIIKXV££AFGVSATPWAA6AVGGTQEAASEVTVKVT 60 1 M KLDK QUESLKEMTI+EIOEIIKAVEEAFGV^ATP+VAAGA g tqeaasev+vkvt Mg: 1 MGKLDKKQLIESLKEMTIVEIDEIIKAVEEATGVTATPIVAAGAASATQEAASSVSVKVT 60 (Please read the note on the back: write this page ) - Installed - Ordered - Ministry of Economic Affairs Intellectual Property Bureau Consumer Cooperatives Μ :: 61 GYTDNAKLAVLKLYREIAGVGLMEAKTAVEKLPCWKQDIKPEEXEELKKRFVEVGATVE 120 GY DNAKLAVLKLYREI GVGLMEAKTAVEKLPCWKQDXKPEEAEELKKHFVEVGArVE Mg: 61 GYADNAKLAVLKLYREITGVGLMEXKTAVEKLPCWKQDIKPEEAEELKKRFVEVGATVE 120

Μρ: 121 IK 122 +KΜρ: 121 IK 122 +K

Mg: 121 VK 122 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐)-8 - 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(6 ) 本發明中微生物係指肺炎黴漿菌之意,特別是於呼吸 器中做爲具有病原性之黴漿菌感染症原因菌之診斷意義極 高之微生物者。本發明中,、、微生物與特異性反應之抗體 〃係指微生物種或屬進行特異性反應之抗體者,而,微生 物感染症之診斷中微生物種之特異性反應之抗體特別有效 〇 本發明中之抗體係指polyclonal抗體,或monoclonal抗 體’可利用該Ribosomal Protein (核糖體)L7/L12蛋白質總 長或其部份胜肽作成之。作成抗體之胜肽長度並無特別限 定,而對於Ribosomal Protein (核糖體)L7/L12蛋白質之抗 體時,只要代表此蛋白質之特徴長度者即可,一般以5胺 基酸以上者宜,特別以8胺基酸以上之胜肽使用者宜。直 接將此胜肽或全長蛋白質或與K L H ( keyhole-limpet hemocyanin ) ,B S A ( bovine serum albumin )之攜帶蛋 白質交聯後必要時與補助劑同時接種於動物後,回收其血 淸後,可取得含有出現Ribosomal Protein (核糖體)L7/L12 蛋白質抗體(polyclonal抗體)之抗血漬。且,由抗血淸精 製抗體後亦可使用之。做爲接種動物者有:綿羊,牛,山 羊’兔子’老鼠,實驗鼠等,於ρ 〇 1 y c 1 q n a 1抗體製作時特別 以綿羊,兔子等爲較佳。又,藉由製作混合細胞之公知方 法亦可取得monoclonal抗體,而此時以老鼠爲宜。 又,以該蛋白質總長或5殘基以上,較佳者8殘基以 上之胺基酸配列做爲谷胱甘酞S -轉換酶(G S T )等與 熔融蛋白質之精製後,或未經精製者可做爲抗原使用之。 (請先閱讀背面之注意事寫本頁) ·. h !i Jr . •裝· 訂 線_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公羞) 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(7 ) 藉由成書(Antibodies; A laboratory manual, E. Harlow et al.,Cold Spring Harbor Laboratory Press )所示各種方法 及基因clomng法等被分離之免疫球蛋白基因經使用後藉由 所培養細胞所發現之基因換組抗體亦可製作之。 對於可做爲本發明標識抗原所使用之Ribosomal Protein (核糖體)L7/L12之抗體可藉由以下方法或其他類似方法取 得,惟,並非僅限於此等方法者。 a ) Ribosomal Protein (核糖體)L7/L12 蛋白質之基 因配列及胺基酸配列針對已知微生物於其微生物中,使與 該蛋白質胺基酸配列類似性少之領域胜肽切片進行合成後 ,以此做爲免疫原製作polyclonal抗體,或monoclonal抗體 後可取得目的之抗體。 又,於已知之該基因兩端使D N A配列做爲檢測之 P C R法後,使基因增幅,相同部分配列做爲鑄模檢測之 混合法等利用一般基因操作手段可取得該基因之全長配列 〇 之後,構成與其他蛋白質基因之熔融基因後,以大腸 菌等做爲宿主後,藉由公知之基因導入法使該熔融基因插 入宿主後,大量發現後做爲熔融蛋白質使用之蛋白質藉由 抗體親和柱體法等進行精製發現蛋白質後可取得目的之蛋 白質抗原。此時Ribosomal Protein (核糖體)L7/L12蛋白質 之全長蛋白質呈抗原因此,針對保存於微生物間之胺基酸 部份即使取得抗體仍不符本發明之目的。因此,對於依本 法取得之抗原藉由公知方法取得monoclonal所產生之混合 (請先閲讀背面之注意事^寫本頁) 裝. 訂 線- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -10 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(8 ) 體後,選擇與該微生物相互反應之抗體所產生之clone後可 取得目的之抗體。 b ) Ribosomal Protein (核糖體)L7/L12 蛋白質之胺 基酸配列爲未知微生物時,其1之Ribosomal Protein (核糖 體)L7/L12蛋白質之胺基酸配列於菌種間爲5 0〜6 0 %呈 相同者,以其胺基酸配列之相同部份配列做爲基藉由 P C R法使特定配列部份之基因增幅,相同部份配列做成 鑄模檢測之混合法等一般基因操作手段使用後可輕易取得 該蛋白質基因。 之後,構成與其他蛋白質基因之熔融基因後,以大腸 菌等做爲宿主後,藉由公知之基因導入法後,使該熔融基 因插入宿主內,大量發現後,針對做爲熔融蛋白質使用之 蛋白質藉由抗體親和柱體法等精製發現蛋白質後,可取得 目的之蛋白質抗原。此時Ribosomal Protein (核糖體) L7/L12蛋白質之全長蛋白質呈抗原,因此,針對保存於微 生物間之胺基酸部份即使取得抗體仍不符本發明目的。因 此,藉由本法取得之抗原相對的藉由公知方法取得 monoclonal抗體所產生之混合體後,選擇與該微生物相互反 應之抗體所產生之clone可取得目的之抗體。 c ) 或以未知之另種方法做爲Ribosomal Protein (核 糖體)L7/L12 .蛋白質之胺基酸配列,進行製作已知之 Ribosomal Protein (核糖體)L7/L12蛋白質胺基酸配列中相 當於保存於微生物間共通配列部份之5〜3 0胺基酸之合 成胜肽,以公知方法針對其胜肽配列製作Polyclonal抗體或 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -11 - (請先閲讀背面之注意事寫本頁) 裝· 訂 線 1282368 經濟部智慧財產局員工消費合作社印製 A7 _ B7 __五、發明説明(9 ) monoclonal抗體。利用該抗體藉由親和柱體色譜法後精製目 的之微生物細胞攪碎液後,可取得高度精製之Ribosomal Protem (核糖體)L7/L12蛋白質。當蛋白質精製度不足時, 公知精製法之離子交換層析法,疏水層析法’凝膠過濾等 方法精製後,藉由所製成之抗體之濕式標繪等方法進行同 定Ribosomal Protein (核糖體)L7/L1 2蛋白貿之彳谷出畫分後 ,取得精製蛋白質。以取得精製Ribosomal Protem (核糖體) L7/L 1 2蛋白質抗原做爲基藉由公知方法取得混合體,選擇 目的微生物之特異反應混合體後,可取得目的之抗體。 該方法a ) ,b )及c )所取得各種微生物中其本發 明特異性抗體可藉由使用各種免疫學分析法後,提供目的 之微生物特異之各種診斷試藥及k i t。例如:此抗體於 公知測定法之聚苯乙烯乳膠之粒子上具有吸著該抗體之凝 聚反應,微纖度板中所進行公知技術之E L I S A法,即 存之免疫色譜法,著色粒子或發色能之粒子,或以酵素或 螢光體被標簽之該抗體同時收集之抗體所被覆之磁性微粒 體等所使用之夾層檢定等已知之所有免疫測定法均可利用 之。 利用抗體之微生物診斷法係指利用於聚苯乙烯乳膠之 粒子上吸附該抗體之凝聚反應,於微纖度板中所進行公知 技術之E L I S A法,既存之免疫色譜法,著色粒子或具 有發色能之粒子,或酵素,抑或螢光體所標簽之該抗體同 時以收集抗體所被覆之磁性微粒子等所使用之夾層檢定等 已知之所有免疫測定方法之診斷方法者。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事¥ π寫本頁) 裝· 訂 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(10 ) 又,特別做爲使用抗體有用之微生物診斷方法者如於 特表平7 - 5 0 9 5 6 5號公報所載之聚矽氧,氮化矽等 所形成之光學薄膜上藉由進行抗體反應之光干擾原理等所 檢出之光學的檢定(〇IA,Optical Immunoassay )等可有效 做爲高感度之診斷方法者。 又,該檢出方法中做爲由必要微生物萃取細胞內標識 抗原之方法者以Triton X-100 ,Tween-20爲始使用各種界 面活性劑藉由萃取試藥之處理法,使用適當之蛋白酶等酵 素之酵素處理法,藉由物理方法後始於微生物細胞攪碎之 已知細胞結構之攪碎方法者被使用之。藉由界面活性劑等 組合後於各微生物依不同試藥設定最適當之萃取條件者宜 〇 又「本發明中,利用抗體之微生物檢測用試藥k i t 相當於使用該檢出方法之檢測用試藥k 1 t者。 肺炎黴獎菌之Ribosomal Protein (核糖體)L7/L12蛋白 質之胺基酸配列及D N A配列示於配列表中。因此,此微 生物可使Ribosomal Protein (核糖體)L7/L12蛋白質之胺基 酸配列於配列表中比較「交叉分型」所記載之類似微生物 同種蛋白質者。合成相同性低之部份胜肽後,針對此作成 polyclonal,或monoclonal抗體可省略選擇對於微生物具特 異性者。 特別是polyclonal抗體時,以蛋白質A柱體等精製免疫 之動物抗血淸後,取得I g G畫分後,更藉由動物免疫所 使用之合成胜肽進行親和精製者宜。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) =13- 一 (請先閱讀背面之注意事 裝-"I π寫本頁) 訂 線 1282368 A7 B7 五、發明説明(11 ) 更且,由該微生物之Ribosomal Protein L7/L12蛋白質 之D N A以N末端與C末端之配列爲基準作成P C R啓發 劑。 利用此P C R啓發劑之相同性,使用格蘭氏D N A藉 由P C R法使D N A切片進行增殖,此經萃取後,依常法 可取得肺炎黴漿菌之Ribosomal Protein L7/L12基因之切片 。肺炎黴漿菌之71/之Rib osomal Protein L7/L12基因之總長 可藉由分析此等切片之D N A配列情報後而得知者。 所取得之肺炎黴漿菌之Ribosomal Protein L7/L12基因 係如:G S T等與熔融蛋白質基因經構成後,利用適當之 發現用胞質遺傳體後構成發現媒介物後,大腸菌等之形質 轉換後,大量發現該蛋白質。適量培養形質轉換之大腸菌 後,以使用G S T之親和柱體進行精製菌體攪碎液後,可 取得肺炎黴漿菌之Ribosomal Protein L7/L12蛋白質與 GST之熔融蛋白質。 直接將此蛋白質,或切斷一部份G S T後,藉由做爲 抗原蛋白質之公知方法確立複數之混合體clone,選擇顯示 肺炎黴漿菌菌體或菌體攪碎後或肺炎黴漿菌之Ribosomal Protein L7/L 1 2蛋白質特異反應之抗體後,可取得目的之 特異性m ο η 〇 c 1 ο n a 1抗體。 以本發明爲基準所製成之抗體可利用於公知測定方法 之聚苯乙烯乳膠粒子上吸附該抗體之凝聚反應,於微纖度 板中所進行公知技術之E L I S A法,既存之免疫色譜法 ’著色法或具有發色能之粒子,抑或酵素或螢光體被標簽 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) _ 14 _ (請先閲讀背面之注意事寫本頁} 、\呑 丁 經濟部智慧財產局員工消費合作社印製 1282368 A7 B7 五、發明説明(12 ) 2該抗體同時被覆於收集抗體之磁性微粒子等所使用之夾 ®檢定等已知所有免疫測定法。 又,以本發明爲基準所製作之抗體於所有免疫測定方 &中,以該抗原蛋白質做爲可於固相或液相中收集之收集 抗體功能,同時藉由公知方法修飾過氧化酶,鹼磷脂酶等 酵素後做成酵素標識抗體之後,亦可做爲檢測用抗體之功 育b 。 〔發明實施之最佳形態〕 以下之例係進行本發明之具體說明者,而,本發明不 僅限於任何範圍者。 〔實施例1〕 將由肺炎黴漿菌之Ribosomal Protein L7/L12基因之 cloning 肺炎黴漿菌(由 A TCC 15531,ATCC 分 割,購入)於加入 Mycoplasma supplement ( D I F C 〇, 0 836 — 68 — 9)之PPL〇瓊脂培養基( D I F C〇,〇4 1 2 — 1 7 — 3 )進行適量植菌後,於 C〇2恆溫下,3 7 °C,5 % C〇2條件下進行培養5小 時。使生育clony最終呈5 X 1 0 9 C F U / m£左右懸浮 於T E緩衝液.(和光純藥工業製)。將1 · 5 4此懸浮液 移至微量離心管後,以1 0,0 0 0 r p m進行2分鐘離 心,去除上澄液。將沈澱部份再懸浮於5 6 7 J之T E緩 衝液。更加入3 0 // 1 1 0 % S D S與3 // 1 20 本紙張尺度適用中國國家標準(CNS ) A4規福210X297公釐1 -15 "~~一 (請先閲讀背面之注意事π —裝--I jc寫本頁) 線 經濟部智慧財產局員工消費合作社印製 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(η ) m g / m£之proteinasek溶液後充份混合之後,於3 7 °c下 進行1小時恆溫。更於5 6 °C下使懸浮液進行1小時恆溫 。再加入8 0 // 1之1 〇%十六基三甲基銨溴化物/ 〇· 7 Μ N a C 1溶液後充份混合之後於6 5 °C下進行 恆溫10分鐘。加入700// 1之同一體積24 : 1之氯 仿-異戊基醇混合液充份攪拌之。 將此溶液於微量離心器以1 2,0 0 〇 r p m,5分 鐘,4 °C下進行離心處理後,將水層畫分移入新微量離心 管。於此充份振動加有0 · 6倍量之異丙醇之管後形成 D N A之沈澱。以玻璃棒吸入白色D N A沈澱後,移入放 有lm£ 7 0%乙醇(一 2 0°C下冷卻者)之另一微量離 心管中。隨後,此管以1 0,0 0 0 r p m進行5分鐘離 心後,小心去除上淸液。加入1 之7 0 %乙醇後,使混 合物更進行5分鐘離心。 再去除上澄液之沈澱溶於1 0 0 // 1之T E緩衝液後 取得D N A溶液。此基因組D N A溶液濃度依Moleculan Cloning. Alaboratory manual, 1989, Eds. Shambrook, J., Fritsch, E.F. and Maniatis,T.,Cold Spring barbor Laboratory Press 之 E5,spectrophotometric Determination of the Amount ofDNAorRNA進行定量。 此基因組D N A中使用1 0 m g ,進行p C R ( polymerase chain reaction ) 。P C R 係使用 Taq plymaerase (寶造酒公司製,編碼R 0 0 1 A )。分別於酵素添加5 Μ 1添加酵素之緩衝液,4 // 1添附酵素之d N T P混合 (請先閲讀背面之注意事 .裝— 寫本頁) 訂 線_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) _ 16 - 1282368 Α7 Β7 五、發明説明(14 ) 物及各2 0 0 p m ο 1之低核苷酸,(配列表配列號碼: 3及4者)。加入精製水使總容量呈5 0 // 1。 將此混合物利用TakaRa PCR Thermal Cycler (熱循環 )480 以 9 5 °C 1 分鐘,5 0 °C 2 分鐘,7 2 °C 3 分 鐙進行5循環後,再以9 5 °C 1分鐘,6 0 °C 2分鐘 ,7 2 t 3分鐘進行2 5循環。使用部份此P C R生成 物後,於1 · 5 %瓊脂糖凝膠中進行電氣泳動。以溴化乙 錠,(日本Zeen公司製)進行染色後,於紫外線下觀察後 ,確定約增幅爲4 0 0 b p之c D N A。利用限制酵素 B a m Η I及X h ο I進行切斷之後,於1 · 5 %瓊脂糖 凝膠中,藉由電氣泳動與溴化乙錠,進行染色。由凝膠切 取約4 0 0 b P譜帶。此於sup re col (寶造酒股份公司製) 進行精製後,插入一般媒介物之P GEX - 6 P - 1( Pharmacia公司製)。同媒介物係使目的之基因切片裝置適 當之限制酵素細胞體,可具有發現與G S T蛋白質之熔融 蛋白質做爲目的分子之發現媒介物功能者。 具體而言,使媒介物P GEX - 6 P - 1與上述 D N A之莫耳比呈1 : 3之混合後,於T 4 D N A連接 酶(In vitro gen公司製)將D N A裝入媒介物中。裝入 DNA之媒介物p GEX — 6 P — 1係於大腸菌之oneshot c 〇 m p e t e n t c e 11藉由基因學方法導入後,再接種於含 5 0 // g/m£之胺苄青黴素(Σ公司)之半固體狀之培養 板L B L -瓊脂培養液(寶造酒股份公司製)。於3 7。(: 使培養板進行1 2小時恆溫後,隨意選取成長之菌落後, 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) · " ' (請先閲讀背面之注意事寫本頁) .裝· 、1Τ 經濟部智慧財產局員工消費合作社印製 1282368 A7 B7 五、發明説明(15 ) 接種於含相同濃度之胺苄青黴素之L -發酵培養液。 3 7 °C下進行8小時振動,培養集菌後’使用Wizard Mimprep ,依添附說明書分離胞質遺傳體。胞質遺傳體係 於限制酵素B a m Η I / X h ◦ I進行切斷處理。切斷約 3 7 0 b p之D N A後,確定P C R生成物之插入。所插 入D N A之鹽基配列決定於所使用之該clone ° 插入D N A切片之鹽基配列決定係利用 Applied Biosystems公司製之螢光Sequences進行實施。 程序採樣之調製係利用PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit ( Applied Biosystems 公司 製)進行之。首先,於0 · 5 之微管中加入9 · 5 // 1 反應液,4 · 0# 1之0 .8pmo 1/// 1之T7助催 化劑(Gibco BRL ),以及 6.5//1 之 0.16//g/ # 1模型D N A進行混合之。以2層1 0 0 // 1之油被 覆混合物後,進行2 5循環P C R增幅處理。其中,1循 環係由9 6 °C下處理3 0秒,5 5 °C下處理1 5秒,以及 6 0 °C下處理4分鐘所成者。於4 °C下,使生成物維持5 分鐘。反應結束後,加入8 0 // 1無菌精製水,進行攪拌 之。使生成物進行離心分離後,以苯酚氯仿進行萃取水層 3次。於1 〇 〇 // 1水層中加入1 〇 // 1 3 Μ醋酸鈉 ρ Η 5 · 2與.3 0 0 // 1之乙醇,進行攪拌之。之後,以 14,0 0 0 r p m,於室溫下進行1 5分鐘離心,回收 沈澱。以7 5 %乙醇洗淨沈澱後,真空下靜置2分鐘後, 進行乾燥後,做成S e q u e n c e (程序)用採樣。S e q u e n c e ( 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事β π寫本頁) 經濟部智慧財產局員工消費合作社印製 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(16 ) 程序)採樣係溶解於含4 // 1 1 0 m Μ之E D T A之甲 醯胺後9 0 °C下進行2分鐘變性。此者於冰中進行冷卻後 供於 S e q u e n c e ο 隨意選自5個clone中之2個具有與使用Ρ C R之檢測 配列之相同性者。又,與Ribosomal Protein(核糖體)L7/L12 蛋白質基因配列相同之D N A配列極爲明顯者。其結構基 因部份之全鹽基配列及所對應之胺基酸配列顯示配列表配 列號碼:1及2之配列者。此基因切片明顯編碼爲肺炎黴 漿菌之Ribosomal Protein(核糖體)L7/L12蛋白質之基因者。 〔實施例2〕 於肺炎黴漿菌之Ribosomal Protein(核糖體)L7/L12基因 之大腸菌中之大量發現與精製。 將裝入發現媒介物之大腸菌於L B培養基中取5 0 J ,37°C下進行培養1天1夜。將5004 2倍濃度之 Y T培養基於3 7 °C下進行加熱1小時。將培養1晚之 5 0 4大腸菌液置入5 0 0 前述培養基中。1小時後, 導入5 5 〇11〇£之1 0 OmM異丙基/3 - D (-)一硫代半 乳吡喃苷(I P T G )後,進行培養4小時。回收生成物 後,移入2 5 0 m£之離心管中,以7 0 〇 〇 r p m進行 1 0分鐘離心。丟棄上澄液後,溶於含5 0 m Μ 丁 r 1 s 緩衝液 ρ Η 7 . 4,2 5 % Sucrose 之各 2 5 溶菌緩衝液。更加入1 · 2 5 10% N P — 4〇, 125// 1,1M MgC 12後,移入塑膠管。冰冷下, 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐)-19 - (請先閲讀背面之注意事\||||填寫本頁) 裝. 訂 線 1282368 經濟部智慧財產局員工消費合作社印製 A7 B7五、發明説明(17 ) 進行5次1分鐘之超首波處理。之後’以 1 2,0 0 0 r p m ’進行離心1 5分鐘’回收上淸液。 再以P B S於調整後之谷胱甘酞瓊脂糖柱體中吸附該 上澄液。再於含2 0 m Μ T r i s緩衝液ρ Η 7 · 4, 4 . 2 m M MgC 12 ’ ImM dithio thretol ( D T T )之洗淨液使柱體進行2床容積份量洗淨。於含有5 m M 谷胱甘酞5 0 m Μ T r i s緩衝液ρ Η 9 · 6中進行溶 離處理。於色素結合法(B r a d f or d法;B i 〇 R a d C 0 ·)決定 溶出畫分之蛋白質含量後,取得主畫分。 所取得精製G S T熔融Ribosomal Protein(核糖體) L7/L12蛋白質純度係藉由電氣泳動法進行確定後,可確保 做爲約7 5 %之免疫源充份之純度者。 〔實施例3〕 針對肺炎黴漿菌Ribosomal Protein(核糖體)L7/L12蛋白 質之monoclonal抗體製作 首先針對老鼠之免疫將1 0 0 // g之肺炎黴漿菌之 G S T熔融Ribosomal Protein(核糖體)L7/L12蛋白質抗原溶 於200// 1之PBS後加入200// 1之夫羅因德之完 全助劑混合之。乳化後取2 0 0 A 1注射於腹腔內。於2 週,4週,及6週後將相同乳化抗原注射於腹腔內。再於 1 0週,1 4週後將2倍濃度之乳化抗原注射於腹腔內。 最後免疫化結束3天之後,摘取脾臟,進行細胞融合。 無菌下取出1 0 8個老鼠脾細胞時取2 X 1 0 7個骨髓 (請先閱讀背面之注意事_ ;寫本頁) -裝- 訂 線 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐)-20 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(ΐδ ) 腫細胞置於玻璃管中充份混合後,以1 5 0 0 r P in進行 5分鐘離心後,丟.棄上澄液後,充份混合細胞。 細胞融合使用之骨髓腫細胞係使用以含1 0 %使用 N S - 1系細胞株之牛胎兒血淸之R Ρ Μ I 1 6 4 0培 養基進行培養後,由細胞融合2週前,以含有 〇.13mM之氮鳥嘌呤,〇 .5//g/m£2MC — 210,10%之牛胎兒血淸之RPMI 1640培養 基進行培養1週後,更於含有1 0 %牛胎兒血淸之 R Ρ Μ I 1 6 4 0培養基進行培養1週者。 於混合細胞試料中加入5 0 之保持於3 7 °C之 R Ρ Μ I 1 6 4 0培養液,以1,5 0 0 r p m進行離 心分離。去除上澄液後,加入1 之保持於3 7 °c 之5 0 %聚乙二醇後,進行攪拌1分鐘。再加入1 〇 2之 保持於3 7 °C之R Ρ Μ I 1 6 4 0培養液,以殺菌過之 吸引管使混合液吸引約5分鐘,排出後劇烈攪拌之。 以1,0 0 0 r p m進行離心分離5分鐘後,去除上 澄液後,加入3 0 m£ H A T培養液使細胞濃度呈5 X 1 0 6 / m£。將此混合物攪拌至均勻後,各以〇 . 1 注入 9 6孔培養板中,於3 7 °C,7%之碳酸氣體氣氛下進行 培養之。分別於第1天,第1週,及第2週加入H A T培 養基後,藉由E L I S A法使產生所期待之抗體細胞進行 ;:已巳 師进。 分別將1 0 0 // 1之以1 0 // g / 濃度分別稀釋溶 於0 · 0 5 %含疊氮化蘇打之Ρ B S之G S T溶_ (請先閲讀背面之注意事Ϊ 艰寫本頁) 裝· 訂 -線 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 21 - 1282368 A7 B7 五、發明説明(19 )Mg: 121 VK 122 This paper size is applicable to the national standard (CNS) A4 specification (210X297 mm)-8 - 1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printing 5, invention description (6) In the present invention Microbial refers to the meaning of M. pneumoniae, especially in the respirator as a microbiologist with a high diagnostic value for pathogenic fungal infections. In the present invention, the antibody and the specific reaction of the microorganism are specific antibodies of the microorganism species or the genus, and the antibody specific for the microbial species in the diagnosis of the microbial infection is particularly effective in the present invention. The anti-system refers to a polyclonal antibody, or a monoclonal antibody, which can be made using the total length of the Ribosomal Protein L7/L12 protein or a partial peptide thereof. The length of the peptide to be made into the antibody is not particularly limited, and for the antibody of the Ribosomal Protein L7/L12 protein, as long as it represents the characteristic length of the protein, it is generally preferred to use a 5-amino acid or more, particularly It is preferred to use a peptide above 8 amino acids. Directly cross-linking the peptide or the full-length protein or the protein carrying KLH (keyhole-limpet hemocyanin) and BSA (bovine serum albumin), and if necessary, inoculation with the auxiliary agent, and recovering the blood stasis, the obtained protein can be obtained. Anti-blood staining of Ribosomal Protein L7/L12 protein antibody (polyclonal antibody). Furthermore, it can also be used after anti-blood sputum antibody preparation. As vaccinated animals, sheep, cattle, goats, 'rabbit' mice, experimental mice, etc., in the production of ρ 〇 1 y c 1 q n a 1 antibody, particularly sheep, rabbits and the like are preferred. Further, a monoclonal antibody can also be obtained by a known method for producing a mixed cell, and at this time, a mouse is preferred. Further, the total length of the protein or 5 residues or more, preferably the amino acid of 8 or more residues, is classified as a glutathione S-converting enzyme (GST) or the like, and is not refined. Can be used as an antigen. (Please read the note on the back to write this page) ·. h !i Jr . • Loading · Setting up _ This paper scale applies to China National Standard (CNS) A4 specification (210X297 public shame) 1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Bureau Employee Consumption Cooperatives Printing 5, Inventions (7) Immune spheres isolated by various methods and gene clomng methods shown in the book (Antibodies; A laboratory manual, E. Harlow et al., Cold Spring Harbor Laboratory Press) The protein gene can also be produced by using a gene-swapping antibody found by the cultured cells after use. The antibody to Ribosomal Protein L7/L12 which can be used as the antigen for the present invention can be obtained by the following method or the like, but is not limited thereto. a) Ribosomal Protein L7/L12 protein gene assignment and amino acid alignment for the known microorganisms in their microorganisms, so that the peptide amino acid with the similarity of the amino acid of the protein is synthesized, By making a polyclonal antibody or a monoclonal antibody as an immunogen, an antibody of interest can be obtained. In addition, after the PCR method in which the DNA is arranged at both ends of the gene as a detection method, the gene is amplified, and the same portion is arranged as a mixed method for mold detection, and the full length of the gene can be obtained by a general genetic manipulation method. After forming a fusion gene with another protein gene, the coagulation gene is inserted into the host by a known gene introduction method, and the protein used as the molten protein is found in a large amount by the antibody affinity column method. After purifying and discovering the protein, the protein antigen of interest can be obtained. At this time, the full-length protein of the Ribosomal Protein L7/L12 protein is an antigen. Therefore, it is not the object of the present invention to obtain an antibody against the amino acid moiety stored between microorganisms. Therefore, the antigen obtained by the method is obtained by a known method to obtain the mixture produced by monoclonal (please read the back of the page first) ^ Install the page. The order of the paper - the paper size applies to the Chinese National Standard (CNS) A4 specification ( 210X297 mm) -10 1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Office Employees' Consumption Cooperatives Printed 5, Inventions (8) After the body, select the clone produced by the antibody that reacts with the microorganism to obtain the antibody of interest. b) When the amino acid of Ribosomal Protein L7/L12 protein is classified as an unknown microorganism, the amino acid of Ribosomal Protein L7/L12 protein of 1 is assigned to 5 0~6 0 % is the same, and the same part of the amino acid is used as a base to increase the gene of the specific part by PCR, and the same part is used as a mixed method such as mold detection. This protein gene can be easily obtained. Then, after forming a fusion gene with another protein gene, the coagulation gene is used as a host, and the fusion gene is inserted into the host by a known gene introduction method. After a large amount of discovery, the protein used as a molten protein is borrowed. After the protein is purified by the antibody affinity column method or the like, the protein antigen of interest can be obtained. At this time, the full-length protein of the Ribosomal Protein L7/L12 protein is an antigen, and therefore, it is not in accordance with the object of the present invention to obtain an antibody against the amino acid moiety stored between the microorganisms. Therefore, by obtaining a mixture of monoclonal antibodies by a known method by the antigen obtained by the present method, the antibody produced by the antibody which reacts with the microorganism can be selected to obtain the desired antibody. c) or use an unknown method as the Ribosomal Protein L7/L12. The amino acid of the protein is formulated to prepare the known Ribosomal Protein L7/L12 protein amino acid in the column. A synthetic peptide of 5 to 30 amino acids co-provided between microorganisms, and a Polyclonal antibody is prepared by a known method for the peptides thereof. The paper is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) - 11 - (Please read the note on the back to write this page) Loading · Booking 1282368 Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printed A7 _ B7 __ five, invention description (9) monoclonal antibodies. The highly purified Ribosomal Protem (ribosomal) L7/L12 protein can be obtained by affinity chromatography using the antibody to purify the desired microbial cell disruption solution. When the protein essence system is insufficient, the ion exchange chromatography method of the purification method, the hydrophobic chromatography method, the gel filtration method, and the like are purified, and the Ribosomal Protein is determined by the wet mapping of the prepared antibody. After the L7/L1 2 protein trade in Shibuya, the refined protein was obtained. The desired antibody can be obtained by obtaining a mixture of a purified Ribosomal Protem (ribosomal) L7/L 1 2 protein antigen by a known method and selecting a specific reaction mixture of the target microorganism. The specific antibodies of the present invention in the various microorganisms obtained by the methods a), b) and c) can provide various diagnostic reagents and k i t specific to the microorganisms of interest by using various immunological assays. For example, the antibody has a coagulation reaction for absorbing the antibody on the particles of the polystyrene latex of the known assay, and an ELISA method using a well-known technique in a microdenier plate, that is, immunochromatography, colored particles or coloring energy All of the known immunoassays, such as sandwich assays used for magnetic microparticles coated with an antibody or a phosphor coated with an antibody which is simultaneously collected by the antibody, can be used. The microbial diagnostic method using an antibody refers to an ELISA method in which a coagulation reaction for adsorbing the antibody on a particle of a polystyrene latex is carried out in a microfibrillary plate, and an existing immunochromatographic method, colored particles or having a coloring property The particle, or the enzyme, or the antibody to which the fluorescent substance is labeled, is a diagnostic method for all known immunoassay methods such as sandwich assay used for collecting magnetic microparticles coated with an antibody. This paper scale is applicable to China National Standard (CNS) A4 specification (210X297 mm) (please read the note on the back first ¥ π write this page) Loading · Book 1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printing 5, invention (10) In addition, as a microbiological diagnostic method useful for the use of antibodies, the optical film formed by polyfluorene, yttrium nitride, etc., as disclosed in Japanese Patent Publication No. 7-5509, The optical assay (〇IA, Optical Immunoassay) detected by the principle of light interference for performing an antibody reaction can be effectively used as a diagnostic method for high sensitivity. In addition, in the method of detecting, the method for extracting the intracellular labeling antigen by the necessary microorganisms is to use Triton X-100, Tween-20 as a starting point to use various surfactants by the method of extracting the reagent, using an appropriate protease, etc. The enzyme treatment method of the enzyme is used by a method of pulverizing a known cell structure which is started by microbial cell disruption by a physical method. It is preferable to set the optimum extraction conditions for each microorganism according to different reagents by combining surfactants, etc. In the present invention, the reagent kit for detecting microorganisms using an antibody is equivalent to the test using the detection method. The drug k 1 t. The Ribosomal Protein of the Pneumoniae Pneumoniae L7/L12 protein is shown in the list and the DNA is shown in the list. Therefore, this microorganism can make Ribosomal Protein L7/L12 The amino acid of the protein is listed in the list to compare the similar microbial proteins described in the "cross-type". After the synthesis of a part of the peptide having the same low identity, the polyclonal or monoclonal antibody can be omitted for the specificity of the microorganism. In particular, in the case of a polyclonal antibody, an animal which has been purified by a protein A column or the like is anti-blood, and after obtaining an I g G score, it is preferable to carry out affinity purification by using a synthetic peptide used for animal immunization. This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) =13- one (please read the note on the back--"I π write this page" Order 1282368 A7 B7 V. Invention description (11 Further, a DNA heuristic agent is prepared from the DNA of the Ribosomal Protein L7/L12 protein of the microorganism based on the arrangement of the N-terminus and the C-terminus. Using the identity of this P C R heuristic, the D N A section was propagated by the P C R method using the granule D N A. After the extraction, the Ribosomal Protein L7/L12 gene of P. pneumoniae was obtained by the usual method. The total length of the Rib osomal Protein L7/L12 gene of 71/M. pneumoniae can be known by analyzing the information of the D N A of these slices. The Ribosomal Protein L7/L12 gene line of the obtained Pneumoniae bacterium is composed of GST and the like, and after the fusion protein gene is formed, the cytoplasmic body is appropriately used to form a discovery medium, and after the shape conversion of the coliform, etc., The protein was found in large quantities. After culturing the form-transformed Escherichia coli in an appropriate amount, the purified cell suspension is obtained by using the affinity column of G S T to obtain the molten protein of Ribosomal Protein L7/L12 protein and GST of M. pneumoniae. After directly cutting the protein, or cutting a part of GST, a complex mixture of clones is established by a known method as an antigenic protein, and it is selected to show that the fungus of the pneumocystis or the fungus is broken or the pneumonia After the Ribosomal Protein L7/L 1 2 protein-specific antibody, the specificity of the target m ο η 〇c 1 ο na 1 antibody can be obtained. The antibody prepared based on the present invention can be adsorbed by the adsorption reaction of the antibody on the polystyrene latex particles of the known measurement method, and the ELISA method of the known technique is carried out in the microdenier plate, and the existing immunochromatographic method is used for coloring. Law or particles with chromogenic energy, or enzymes or phosphors are labeled to the Chinese National Standard (CNS) A4 specification (210X297 mm) _ 14 _ (please read the note on the back first) \ Kenting Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed 1282368 A7 B7 V. Inventive Note (12) 2 This antibody is also coated with all known immunoassays such as the clamp® test used for collecting magnetic particles such as antibodies. The antibody produced based on the present invention is used in all immunoassays, and the antigen protein is used as a collection antibody function which can be collected in a solid phase or a liquid phase, and the peroxidase and the base are modified by a known method. After the enzyme such as phospholipase is used as an enzyme-labeled antibody, it can also be used as a test for the antibody b. [Best form of invention] The following example is Specifically, the present invention is not limited to any range. [Example 1] Cloning of the Ribosomal Protein L7/L12 gene of P. oxysporum was isolated from A TCC 15531, ATCC, and purchased. ) After adding appropriate amount of bacteria to PPL〇 agar medium (DIFC〇, 〇4 1 2 - 1 7 3) added to Mycoplasma supplement (DIFC 〇, 0 836 — 68-9), at a constant temperature of C〇2, 3 7 Incubate for 5 hours at a temperature of 5 % C〇2. Let the fern clone finally be suspended in TE buffer at a rate of 5 X 1 0 9 CFU / m. (made by Wako Pure Chemical Industries, Ltd.) 1. 5 4 After the suspension was transferred to a microcentrifuge tube, it was centrifuged at 10 00 rpm for 2 minutes to remove the supernatant. The precipitate was resuspended in 5 6 7 J of TE buffer. Add 3 0 // 1 10% SDS and 3 // 1 20 This paper scale applies to China National Standard (CNS) A4 Regulation Fu 210X297 mm 1 -15 "~~1 (Please read the note on the back first π - Install - I jc write This page) Ministry of Economic Affairs, Intellectual Property Bureau, Staff Consumer Cooperatives, Printing 1282368 A7 B7 Ministry of Economic Affairs, Intellectual Property Bureau The consumer consumption cooperative printed five, the invention (η) mg / m £ proteinasek solution, after mixed mixing, at 1 7 °c for 1 hour constant temperature. At 5 6 ° C, the suspension was kept at constant temperature for 1 hour. . Further, 80 0 / 1 1 〇 % hexadecyltrimethylammonium bromide / 〇 · 7 Μ N a C 1 solution was added and mixed thoroughly, and then kept at 65 ° C for 10 minutes. Add 700/1 of the same volume of 24:1 chloroform-isoamyl alcohol mixture and mix well. The solution was centrifuged at 1 2,0 0 〇 r p m for 5 minutes at 4 °C, and the aqueous layer was transferred to a new microcentrifuge tube. A sufficient precipitation of D N A was formed by adding a tube of 0.6 ppm of isopropanol to the vibration. After inhaling the white D N A precipitate with a glass rod, it was transferred to another microcentrifuge tube containing lm £ 70% ethanol (cooled at 20 ° C). Subsequently, the tube was centrifuged at 10,0 0 0 r p m for 5 minutes, and the supernatant was carefully removed. After adding 1 70% ethanol, the mixture was further centrifuged for 5 minutes. The D N A solution was obtained by removing the precipitate of the supernatant solution and dissolving it in 1 0 0 //1 T E buffer. The concentration of this genomic D N A solution was quantified according to Moleculan Cloning. Alaboratory manual, 1989, Eds. Shambrook, J., Fritsch, E.F. and Maniatis, T., Cold Spring Barbor Laboratory Press E5, spectrophotometric Determination of the Amount of DNAorRNA. In this genomic D N A, 10 μg was used to carry out p C R (polymerase chain reaction ). P C R is a Taq plymaerase (manufactured by Takara Co., Ltd., code R 0 0 1 A). Add 5 Μ 1 added enzyme buffer to the enzyme, 4 // 1 add enzyme NTP mix (please read the note on the back first. Install - write this page) Set _ This paper scale applies to Chinese national standard (CNS A4 size (210X297 mm) _ 16 - 1282368 Α7 Β7 V. Description of invention (14) and each oligonucleotide of 2 0 0 pm ο 1 (with list number: 3 and 4). Add purified water to make the total capacity 5 0 // 1. This mixture was subjected to TakaRa PCR Thermal Cycler 480 at 9 5 ° C for 1 minute, 50 ° C for 2 minutes, 7 2 ° C for 3 minutes, and then at 95 ° C for 1 minute, 6 2 ° cycle at 0 °C for 2 minutes, 7 2 t for 3 minutes. After a portion of this P C R product was used, electrophoresis was carried out in a 1.9 % agarose gel. After dyeing with ethidium bromide (manufactured by Zeen, Japan), after observation under ultraviolet light, c D N A having an increase of about 400 b was determined. After cutting with restriction enzymes B a m Η I and X h ο I, staining was carried out by electrophoresis with ethidium bromide in a 1.5% agarose gel. A band of about 400 b P was cut from the gel. This was purified by Sup re col (manufactured by Takara Co., Ltd.), and then inserted into a general vehicle P GEX - 6 P - 1 (manufactured by Pharmacia Co., Ltd.). The same kind of media system allows the target gene slicing device to appropriately restrict the enzyme cell body, and can have a function of finding a vehicle function as a molecular molecule of the fusion protein of G S T protein. Specifically, the molar ratio of the vehicle P GEX - 6 P - 1 to the above D N A was 1:3, and then D N A was placed in the vehicle under a T 4 D N A ligase (manufactured by In vitro). The DNA-loaded vehicle p GEX — 6 P — 1 is in the oneshot c 〇mpetentce 11 of Escherichia coli and then inoculated into the ampicillin containing 50 // g/m £ (Σ) A semi-solid culture plate LBL-agar culture solution (manufactured by Takara Co., Ltd.). At 3 7. (: After the culture plate is kept at a constant temperature for 12 hours, the growth bacteria are randomly selected. The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) · " ' (Please read the note on the back first) Page) . Loading · , 1Τ Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed 1282368 A7 B7 V. Invention Description (15 ) Inoculated in L-fermentation culture solution containing ampicillin at the same concentration. 3 7 °C After shaking for a few hours, after cultivating the bacteria, use the Wizard Mimprep and separate the cytoplasmic genetics according to the instructions. The cytoplasmic genetic system is cut off by the restriction enzyme B am Η I / X h ◦ I. The cut is about 370 bp. After the DNA, the insertion of the PCR product is determined. The salt-based arrangement of the inserted DNA is determined by the use of the fluorescent sequence of the inserted DNA fragment of the clone. The determination is performed by using the fluorescent sequence of Applied Biosystems. This was carried out by using PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems). First, adding 9 · 5 // 1 reaction to 0 · 5 microtubes , 4 · 0# 1 of 0. 8pmo 1/// 1 of T7 Promoter (Gibco BRL), and 6.5//1 of 0.16//g/ # 1 model DNA for mixing. With 2 layers of 1 0 0 / After the oil coating of /1 is carried out, 25 5 PCR amplification treatment is carried out, wherein 1 cycle is treated at 9 6 ° C for 30 seconds, at 5 5 ° C for 15 seconds, and at 60 ° C for treatment 4 In the minute, the product was maintained at 5 ° C for 5 minutes. After the reaction was completed, 80 0 / 1 sterile purified water was added and stirred. The product was centrifuged and extracted with phenol chloroform. Layer 3 times. Add 1 〇// 1 3 Μ sodium acetate ρ Η 5 · 2 and .3 0 0 // 1 ethanol to the 1 〇〇// 1 water layer and stir. After that, 14,0 The mixture was centrifuged at room temperature for 15 minutes at room temperature to recover the precipitate. The precipitate was washed with 75% ethanol, and then allowed to stand under vacuum for 2 minutes, then dried, and then sampled for Sequence. Equence (This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) (please read the note on the back of the book π π write this page) Ministry of Economic Affairs Intellectual Property Office staff The fee cooperative printed 1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printing 5, invention description (16) Procedure) The sampling system is dissolved in the EDTA containing 4 // 1 10 m Μ after the methamine 90 ° C Denaturation was carried out for 2 minutes. This person is cooled in ice and supplied to S e q u e n c e ο. Two of the five clones are randomly selected to have the same identity as the detection using Ρ C R . Further, the D N A arrangement identical to the Ribosomal Protein L7/L12 protein gene is extremely obvious. The full-salt arrangement of the structural part of the structure and the corresponding amino acid arrangement show the matching list number: 1 and 2. This gene section was clearly encoded as a gene for the Ribosomal Protein L7/L12 protein of M. pneumoniae. [Example 2] A large amount of discovery and purification in Escherichia coli of the Ribosomal Protein L7/L12 gene of M. pneumoniae. The coliforms in which the vehicle was found were taken in 50 B of L B medium, and cultured at 37 ° C for 1 day and 1 night. 5004 2 times the concentration of Y T medium was heated at 37 ° C for 1 hour. The 504 coliform solution cultured for 1 night was placed in the above-mentioned medium of 500. After 1 hour, 5 5 OmM isopropyl/3-D (-) monothiogalactopyranoside (I P T G ) was introduced and cultured for 4 hours. After recovering the product, it was transferred to a centrifuge tube of 250 ml, and centrifuged at 70 〇 〇 r p m for 10 minutes. After discarding the supernatant, it was dissolved in 2 5 lysis buffer containing 50 m Μ r 1 s buffer ρ Η 7.4, 2 5 % Sucrose. Add 1 · 2 5 10% N P — 4〇, 125// 1,1M MgC 12, then move into the plastic tube. Under cold weather, this paper scale applies to China National Standard (CNS) A4 specification (210X 297 mm)-19 - (Please read the note on the back first]||||fill this page. Install. Order 1282368 Ministry of Economics Intellectual Property Bureau employee consumption cooperative printed A7 B7 V. Invention description (17) 5 times 1 minute super first wave processing. Thereafter, the mixture was centrifuged at 1 2,0 0 0 r p m ' for 15 minutes to recover the supernatant. The supernatant was then adsorbed by P B S in the adjusted glutathione agarose column. The column was washed in a 2 bed volume by a washing solution containing 20 m Μ T r i s buffer ρ Η 7 · 4, 4 . 2 m M MgC 12 ' ImM dithio thretol ( D T T ). Dissolution treatment was carried out in a buffer containing 5 m M glutathione 50 m Μ T r i s buffer ρ Η 9 · 6. After the pigment binding method (B r a d f or d method; B i 〇 R a d C 0 ·) determines the protein content of the dissolved fraction, the main drawing score is obtained. The purified G S T melted Ribosomal Protein (ribosomal) L7/L12 protein purity is determined by the electrophoresis method to ensure the purity of about 75% of the immune source is sufficient. [Example 3] Monoclonal antibody against Ribosomal Protein L7/L12 protein of Mycoplasma pneumoniae was firstly immunized against mice. The GST fusion of Ribosomal Protein (ribosomes) of 1 0 0 // g of M. pneumoniae The L7/L12 protein antigen was dissolved in 200//1 PBS and then mixed with 200//1 of Freund's complete adjuvant. After emulsification, 200 A 1 was injected into the abdominal cavity. The same emulsified antigen was injected into the abdominal cavity at 2 weeks, 4 weeks, and 6 weeks later. Further, at 10 weeks, a 2-fold concentration of the emulsified antigen was injected into the abdominal cavity after 14 weeks. Three days after the end of the final immunization, the spleen was removed and cell fusion was performed. Take 2 X 107 bone marrow when removing 10 8 mouse spleen cells aseptically (please read the notes on the back _; write this page) - Pack - Set the paper size to the Chinese National Standard (CNS) A4 specifications (210 X 297 mm)-20 1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed V. Inventive Note (ΐδ) After swollen cells are placed in a glass tube and mixed thoroughly, 1 500 edge in P in After centrifugation for 5 minutes, discard. After discarding the clear solution, mix the cells thoroughly. The myeloid cell line used for cell fusion was cultured with R Ρ Μ I 1 60 40 medium containing 10% of bovine fetal blood sputum using NS-1 cell line, and then fused with cells 2 weeks before cell fusion. .13 mM azoguanine, 〇.5//g/m £2MC — 210, 10% fetal calf RPMI 1640 medium was cultured for 1 week, and more than 10% bovine fetal blood sputum R Ρ Μ I 1 6 4 0 medium was cultured for 1 week. 50 liters of R Ρ Μ I 1 6 4 0 culture solution maintained at 37 ° C was added to the mixed cell sample, and centrifugation was performed at 1,500 rpm. After the supernatant was removed, 1% of the polyethylene glycol maintained at 3 7 ° C was added, and the mixture was stirred for 1 minute. Then, add 1 〇 2 of R Ρ Μ I 1 6 4 0 culture solution maintained at 3 7 ° C, and sterilize the suction tube to attract the mixture for about 5 minutes, and vigorously stir it after discharge. After centrifugation at 1,0 0 0 r p m for 5 minutes, after removing the supernatant, a 30 m £H A T culture solution was added to bring the cell concentration to 5 X 1 0 6 / m £. After the mixture was stirred until homogeneous, each was poured into a 96-well culture plate with 〇.1, and cultured at 37 ° C under a carbon dioxide atmosphere of 7%. After the addition of the H A T medium on the first day, the first week, and the second week, the desired antibody cells were produced by the E L I S A method; Divide 1 0 0 // 1 to 1 0 // g / concentration separately and dissolve in 0 · 0 5 % containing azide soda Ρ BS GST solution _ (please read the back note first) Page) Loading and binding - The paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm) 21 - 1282368 A7 B7 V. Invention description (19)

Ribosomal Protein(核糖體)L7/L12蛋白質及G S T蛋白質注 入9 6孔培養板中,於4 °C下進行吸附1晚。 去除上澄液後,添加2 0 0 // 1 1 %牛血淸白蛋白 溶液(P B S中),室溫下反應1小時後進行截止。去除 上澄液後,以洗淨液(0 · 0 2 % Tween 20, P B S )將生成物洗淨。於此加入1 〇 2融合細胞之培養 液,室溫下進行反應2小時。去除上澄液後,以洗淨液將 沈澱洗淨。再加入1 0 0 // 1之於濃度5 0 m g / 2之過 氧化物酶經標簽後之g o a t a n t i - m o u s e I g G抗體溶液,室溫下 反應1小時。去除上澄液後,再次以洗淨液洗淨生成物。 分別加入100//1之TMB溶液(KPL公司製),室 溫下使混合物進行反應2 0分鐘。於著色後加入 .1 0 0 // 1 1 N硫酸後,停止反應,測定4 5 0 n m之 吸光度。 此結果判定對於於G S T熔融Ribosomal Protein(核糖 體)L7/L12蛋白質反應後,發現於G S T蛋白質未反應之陽 性Wale之Ribosomal Protein(核糖體)L7/L12蛋白質爲含有 抗體者。 因此,於分別回收陽性Wale中細胞之2 4孔塑膠板中 以H A Y培養基進行培養之。 使培養之融合培養基呈細胞數約爲2 0個/ 之Η T 培養基下進行稀釋後,取5 0 μ 1與Η Τ培養基所懸浮之 6週齡老鼠胸腺細胞1 〇 6個於9 6孔培養板中進行混合之 。混合後,於7 % C 0 2條件下,3 7 °C,進行培養2週 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐)_ 22 - (請先閱讀背面之注意事π •裝l· — ¾舄本頁) 經濟部智慧財產局員工消費合作社印製 1282368 經濟部智慧財產局員工消費合作社印製 A7 B7五、發明説明(20 ) 〇 以前述E L I S A法同樣進行檢定培養上澄液中之抗 體活性後,回收與Ribosomal Protein L7/L12蛋白質之反應 陽性細胞。更進行相同之稀釋檢定,重覆cloinng操作,取 得混合體Μ P R B — 1〜5共5 clone。 〔實施例4〕 檢測肺炎黴漿菌之Ribosomal Protein(核糖體)L7/L12蛋 白質之monoclonal抗體之選擇 利用前述所取得之陽性混合體細胞依所定方法進行 monoclonal抗體之生產回收。 具體而言,利用R Ρ Μ I 1 6 4 0培養基(加1 0 % F C S )預先於2週前使傳代培養細胞於腹腔內注射 0 · 5 mC十八碳烷之Blab/C老鼠腹腔內注射5 X 1 0 6個( P B S中)。回收3週之腹水後,取得其離心上澄液。 將所使得含抗體溶液於Protein A柱體(5 , Pharmacia製)被吸收後,以3倍量之P B S進行洗淨。再 以檸檬酸緩衝液於ρ Η 3下進行溶出。回收抗體畫分後’ 藉由各結合體取得所產生之monoclonal抗體。使用原於此 5株結合體之monoclonal抗體後藉由E L I S A法進行§平 定。 monoclonal抗體之評定中使用夾層分析法者。所作成 monoclonal抗體結合於過氧化物酶時做爲檢測抗體之使用° 酵素標識係使用山葵過氧化物酶,(Sigma gled VI )結合 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)-23 - (請先閲讀背面之注意言7" 裝· 訂 線 1282368 A7 B7 五、發明説明(21 ) 係使用試藥S -乙醯硫代醋酸N -羥基琥珀乙胺後,藉由 生物化學分析132 (1983) ,68 — 73所述之方 法進行之。E L I S A法反應中係於9 6孔培養板中分別 以1 0 0 // 1以1 0 // g / 濃度所稀釋之市販抗肺炎黴 獎菌polyclonal抗體(Biodesign公司,兔子)後,於4 下進行吸附1晚。 去除上澄液後,添加2 0 0 # 1 1 %牛血淸白蛋白 溶液(P B S中)後,室溫下進行1小時反應後截止。去 除上澄液後,以洗淨液(0 · 0 2 % Tween 2 〇 ,P B S )進行洗淨生成物。於此加入各微生物培養液呈 〇· 3 %濃度之Trhon X-100後,常溫下,加入萃取5分鐘 後取得之1 0 0 // 1抗原溶液,室溫下反應2小時。去除 上澄液後再次以洗淨液洗淨生成物。再加入1 0 0 // 1濃 度5 A g / rn£之過氧化物酶標識抗Ribosomal Protein(核糖 體)L7/L12蛋白質抗體溶液後,室溫下,反應1小時。去除 上澄液後,再次以洗淨液洗淨生成物。各加入1 0 0 // 1 Τ Μ B溶液(K P L公司製),於室溫下使混合物反應 20分鐘。著色下加入100// 1 1Ν硫酸後,停止反 應。測定4 5 0 n m之吸光度。 以原於混合體Μ P R B — 1之monoclonal抗體做爲酵 素標識抗體使用時,以1 0 8個/ 之感度檢測所有試驗肺 炎黴漿菌之株之同時,針對其他流行感冒桿菌,肺炎桿菌 ,肺炎披衣菌及腦0吴炎球菌等微生物於1 0 8個/ 之高濃 度下仍未顯不反應性對於Ribosomal Protein(核糖體)L7/L12 (請先閲讀背面之注意事Ϊ .¾-- π寫本頁) 丁 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) _ 24 - 1282368 A7 B7 五、發明説明(22 ) 蛋白質使用monoclonal抗體後,可淸楚確定取得具肺炎徽 槳菌之特異反應性者。此抗體稱爲A Μ Μ P - 1。表2 g 代表使用A Μ Μ P - 1之結果。此未提及使用與另外微生 物相互交差反應所顯示其他抗體後之結果。 表2 檢出結果(1 06 cells/m£ ) pneumoniae(肺炎黴槳菌) + 檢出結果(10 cells/m£ ) N.meningitides(腦膜炎球菌) - N. 1 a c t a m i c e (嗜乳糖萘瑟氏菌) - N.mucosa(黏膜奈瑟菌) - N. s i c c a (乾燥耐色氏球菌) - H.influenzae(流行感冒桿菌) - B.catarrharis(黏膜炎菌) - N.gonorrhoeae(淋病奈瑟菌) - E.coli(大腸桿菌) - K.pneumoniae(肺炎桿菌) - (+;正、-;負) 經濟部智慧財產局員工消費合作社印製 〔實施例5〕 使用Ribosomal Protein(核糖體)L7/L12蛋白質固定化之 親和抗體取得與肺炎黴槳菌Ribosomal Protein(核糖體) L7/L12蛋白質之特異反應polyclonal抗體 以藉由實施例1所載方法後取得之肺炎黴漿菌 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -25 - 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(23 ) Ribosomal Protein(核糖體)L7/L12 蛋白質或 Triton X-100 處 理之菌體上淸液做爲抗原使用之。使含1 〇 〇 // g抗原之 約1 · 2 m£生理食鹽水與1 · 5 m£之夫羅因德助劑同時乳 化之。使於S P F日本白色兔子中以皮下注射乳化劑之兔 子進行免疫化。每2週免疫5〜6次後,確定抗體價。 抗體價之確定係依E L I s A法進行者。溶於含 0 · 0 5 %疊氮化蘇打P B S中之肺炎黴漿菌之Ribosomal Protein(核糖體)L7/L12蛋白質稀釋成1 〇 // g/2濃度之 液體分別以1 0 0 // g注入9 6孔培養板後,進行吸附1 晚。去除上澄液後,添加2 0 0 // 1之1 %牛血淸白蛋白 溶液(P B S中)後,室溫下反應1小時後進行。去除上 澄液後,以洗淨液(0 · 0 2 % Tween 20, P B S )洗淨生成物。加入1 〇 〇 // 1稀釋正常兔子血淸 及免疫化兔子之抗血淸後取得之溶液,室溫下進行反應2 小時。去除上澄液後,再以洗淨液進行洗淨生成物。再加 入100// 1之濃度50//g/m£之過氧化物酶標識抗兔 子I g G抗體溶液後,室溫下反應1小時。去除上澄液後 ,再次以洗淨液洗淨生成物。各加入1 0 0 // 1之〇 P D 溶液(Σ公司製),使混合物於室溫下反應2 0分鐘。著 色後加入1 0 0 // 1 1 N硫酸之後停止反應。測定 4 9 2 n m之吸光度。 確定抗體價上昇後,進行大量採血。於玻璃製離心管 中採取由耳動脈之血液後,於3 7 t下放置1小時後, 4 °C下靜置1晚。之後以3 0 0 0 r p m進行5分鐘離心 (請先閲讀背面之注意事寫本頁) -裝· 訂 -線 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) _ 26 - 1282368 A7 B7 五、發明説明(24 ) ,回收上淸液。取得抗血淸保存於4 °C。 進行調製固定化肺炎黴漿菌之Ribosomal Protein(核糖 體)L7/L12蛋白質之親和柱體者。利用Hi Trap NHS活化柱 體(1 ,phamacia公司製)。以1 m Μ H C 1取代柱 體後立刻加入Ribosomal Protein(核糖體)L7/L12蛋白質之 P B S溶液(1 m g /2)。使柱體靜置3 0分鐘後,加 入黏連試藥後,於P B S進行平衡化。 使用此肺炎黴漿菌之Ribosomal Protein(核糖體)L7/L12 蛋白質固定化親和柱體之後,進行精製以肺炎黴漿菌之 Triton X-100處理之菌體上淸液做爲抗原取得之抗血淸中 polyclonal抗體。此抗血淸以P B S稀釋成5倍後,通過 〇· 4 5 // m之濾器後,以流速0 · 5 / m i η吸附肺 炎黴獎菌之Ribosomal Protein(核糖體)L7/L12蛋白質固定化 柱體。之後,以0 i 1 Μ甘胺酸緩衝液於P Η 2 · 1下由 柱體溶出,立刻以1 Μ T r i s緩衝液於ρ Η 9 · 0進 行中和,藉由與抗體價測定法相同之E L I S Α法回收目 的之抗體溶出畫分。 如此取得之poly clonal抗體係藉由特表平7 — 5 0 9 5 6 5號公報所載〇I A法進行評定者。 精製後之抗體係做爲〇I A法之收集抗體使用者。又 ,做爲檢測抗體者以過氧化物酶使用實施例4所載之 AM C T — 1 monoclonal抗體進行酵素標識者。酵素標 識係於使用山葵之過氧化酶(Σ gled VI )結合中依試藥S -乙醯硫醋酸N -經基琥珀亞胺所使用之生物化學分析 (請先閲讀背面之注意事π •裝-- π寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) -27 - 1282368 A7 _ B7 _ 五、發明説明(25 ) 1 3 2 ( 1 9 8 3 ),6 8 - 7 3所述方法進行之。 〇I A反應中,於聚矽氧晶圓上各添加5 0 # 1之以 0.1M HEPES緩衝液ρΗ8·0下使含〇·〇5 %疊氮化鈉PBS中之精製polyclonal抗體稀釋成l〇//g / 濃度之液體後,室溫下反應3 0分鐘之後,以蒸餾水 進行洗淨,以含有蔗糖以及鹼處理酪素之塗佈液進行塗層 後使用之。 上述操作所取得之各微生物培養液中加入濃度爲 0 . 5 %量之Triton X-100後,常溫下萃取5分鐘後,取得 1 5 // 1之抗原溶液添加於該聚矽氧晶圓後,室溫下,反 應1 0分鐘。再加入1 5 // 1之2 0 // g / 過氧化物酶 標識化monoclonal抗體,反應1 〇分鐘。以蒸餾水洗淨後 ,各加入1 5 // 1 Τ Μ B溶液(K P L公司製),使混 合物於室溫下反應5分鐘。以蒸餾水洗淨生成物,以肉眼 觀察酵素反應所生成之青色。 此結果,如表3所示,以精製polyclonal抗體A Ρ Μ Ρ - 1做爲收集抗體使用後,以1 0 8個/j之感度可明顯顯 示可檢測肺炎黴漿菌與無法檢測其他微生物之反應性者。 藉由此固定化肺炎黴獎菌之Ribosomal Protein(核糖體) L7/L12蛋白質之親和柱體之後,確定可取得肺炎黴漿菌之 特異反應polyclonal抗體者。 本紙張尺度適用中國國家標準(CNS ) A4規格(210x297公釐) (請先閱讀背面之注意事 :寫本頁) 經濟部智慧財產局員工消費合作社印製 1282368 A7 B7 五、發明説明(26 表 檢出結果 (10 8 cells/mC ) M. pneumoniae(肺炎黴漿菌) + H.influenzae(流行感冒桿菌)ATCC10211 - E.coli(大腸桿菌) ATCC25922 - E.faecalis(糞便桿菌) ATCC19433 - K.pneumoniae(肺炎桿菌) ATCC 1 3 8 8 3 - N.gonorrhoeae(淋病奈瑟菌) IID821 - N.l act amice (嗜乳糖萘瑟氏菌)ATCC 2 3 970 N. m e n i n g i t i d e s (腦膜炎球菌) ATCC13090 - P.aeruginosa(綠膿桿菌) ATCC27853 - GroupB Streptococcus (B群鏈球菌屬) ATCC12386 _ S.aureus(金色鏈球菌) ATCC25923 - S.pneumoniae(肺炎鏈球菌) ATCC27336 哪 S.pyogenes(釀膿鏈球菌) ATCC19615 - (請先閲讀背面之注意事舄本頁) -裝· 訂 線 經濟部智慧財產局員工消費合作社印製 (+ ;正、-;負) 〔產業上可利用性〕 根據本發明於微生物進行過程中針對有效被保持之細 胞內分子使用抗體後不僅可特異的檢測特定種之微生物’ 亦可於同一種內檢測良好精密度之所有血淸型之微生物° 以微生物之核糖核蛋白體蛋白質,Ribosomal Protemi 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -29 - 1282368 A7 B7 五、發明説明(27 ) 核糖體)L7/L12蛋白質之抗體做爲此抗體之使用後,可進行 精密度良好之肺炎黴槳菌之檢測。 又,以微生物檢測用試藥k i t做爲構成此抗體之要 素使用後,可進行更廣泛且良好精密度之微生物的檢測。 (請先閲讀背面之注意事 :寫本頁) -裝·The Ribosomal Protein L7/L12 protein and G S T protein were injected into a 96-well culture plate and adsorbed for 1 night at 4 °C. After the supernatant was removed, a solution of 2 0 0 // 1 1 % bovine blood albumin (in P B S) was added, and the reaction was terminated at room temperature for 1 hour. After removing the supernatant, the product was washed with a washing solution (0 · 0 2 % Tween 20, P B S ). A culture solution of 1 〇 2 fused cells was added thereto, and the reaction was carried out for 2 hours at room temperature. After removing the supernatant, the precipitate is washed with a washing solution. Further, 10 0 / 1 of a peroxidase-labeled peroxidase of g o a t a n t i - m o u s e I g G antibody solution was added, and the reaction was carried out for 1 hour at room temperature. After removing the supernatant liquid, the product was washed again with a washing solution. A 100//1 TMB solution (manufactured by KPL Co., Ltd.) was separately added, and the mixture was allowed to react at room temperature for 20 minutes. After the coloring was added to .1 0 0 // 1 1 N sulfuric acid, the reaction was stopped, and the absorbance at 450 n m was measured. As a result, it was judged that the Ribosomal Protein L7/L12 protein which is found to be unreactive in the G S T protein and reacted with the G S T melted Ribosomal Protein L7/L12 protein is an antibody-containing antibody. Therefore, it was cultured in a 24 μm plastic plate in which the cells in the positive Walle were separately recovered in H A Y medium. The culture medium was cultured in a number of cells of about 20 cells/min. After dilution in T medium, 50 μl of the thymocytes of 6-week-old mice suspended in Η Τ medium were cultured in 1 6 cells in 96 cells. Mix in the plate. After mixing, culture at 2 7 °C for 7 weeks under 7 % C 0 2 conditions. This paper scale applies to Chinese National Standard (CNS) A4 size (210 X 297 mm) _ 22 - (Please read the back of the note first) π • Install l· — 3⁄4舄 Page) Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed 1282368 Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed A7 B7 V. Invention Description (20) 同样 Same as the above ELISA method After culturing the antibody activity in the supernatant, the positive cells reactive with Ribosomal Protein L7/L12 protein were recovered. Perform the same dilution test and repeat the cloinng operation to obtain a mixture of Μ P R B — 1 to 5 for 5 clones. [Example 4] Selection of Monoclonal Antibody for Ribosomal Protein L7/L12 Protein of M. pneumoniae The positive mixed cells obtained as described above were used for production recovery of monoclonal antibodies according to the predetermined method. Specifically, the subcultured cells were intraperitoneally injected with 0·5 mC octadecane in the peritoneal cavity of Blab/C mice by using R Ρ Μ I 1 6 4 0 medium (plus 10% FCS). Inject 5 x 106 (in PBS). After recovering the ascites for 3 weeks, the supernatant was obtained by centrifugation. After the antibody-containing solution was absorbed in a Protein A column (5, manufactured by Pharmacia), it was washed with 3 times the amount of P B S . Further, the solution was eluted with citric acid buffer at ρ Η 3 . After the antibody was collected, the monoclonal antibody produced was obtained by each of the conjugates. Using the monoclonal antibodies of the above 5 conjugates, § was determined by the E L I S A method. A sandwich assay is used in the evaluation of monoclonal antibodies. The monoclonal antibody is used as a detection antibody when it binds to peroxidase. The enzyme identification system uses horseradish peroxidase, and (Sigma gled VI) is combined with this paper scale to apply Chinese National Standard (CNS) A4 specification (210X297 mm). )-23 - (Please read the note on the back 7" Loading and setting 1282368 A7 B7 V. Invention description (21) After using the reagent S-acetamidine thioacetic acid N-hydroxysuccinamine, by biological Chemical analysis 132 (1983), 68-73. The ELISA method was carried out in a 96-well culture plate diluted with 1 0 0 // 1 at a concentration of 10 // g / respectively. After the Pneumococcal polyclonal antibody (Biodesign, rabbit), the adsorption was carried out for 1 night at 4 times. After removing the supernatant, add 2 0 0 # 1 1 % bovine blood albumin solution (in PBS), room temperature After the reaction was completed for 1 hour, the supernatant was removed, and the supernatant was washed with a washing solution (0 · 0 2 % Tween 2 〇, PBS), and each microbial culture solution was added thereto at a concentration of 3%. After Trhon X-100, at room temperature, add extraction for 5 minutes. 1 0 0 // 1 antigen solution, react at room temperature for 2 hours. After removing the supernatant solution, wash the product again with a washing solution. Add 10 0 / 1 concentration 5 A g / rn £ peroxidation After identifying the anti-Ribosomal Protein L7/L12 protein antibody solution, the enzyme was reacted for 1 hour at room temperature. After removing the supernatant solution, the product was washed again with a washing solution. Each was added to 1 0 0 // 1 Τ Μ B solution (KPL company), the mixture was reacted at room temperature for 20 minutes. After adding 100//1 1 Ν sulfuric acid under coloring, the reaction was stopped. The absorbance at 450 nm was measured. When monoclonal antibody is used as an enzyme-labeled antibody, all strains of M. pneumoniae are tested at a sensitivity of 108 per sensitivities, and other influenza bacilli, pneumonia, pneumonia, and cerebral Microorganisms such as cocci are still not reactive at a concentration of 108 / for Ribosomal Protein L7/L12 (please read the note on the back. 3⁄4-- π write this page) Ding Economics Department Intellectual Property Bureau employee consumption cooperative printed this paper scale applicable to China Quasi (CNS) A4 size (210X297 mm) _ 24-- after five 1282368 A7 B7 described (22) using monoclonal antibody proteins invention, may be made with a specific determined Qing Chu logo pneumoniae bacteria of the paddle are reactive. This antibody is called A Μ Μ P - 1. Table 2 g represents the result of using A Μ Μ P - 1. This does not mention the results of using other antibodies shown by cross-reacting with other microorganisms. Table 2 Results of detection (1 06 cells/m£) pneumoniae (proteobacteria) + detection results (10 cells/m£) N.meningitides (meningococcal) - N. 1 actamice (lactose naphthyl) Bacteria - N.mucosa - N. sicca - H. influenzae - B. catarrharis - N. gonorrhoeae (Neisseria gonorrhoeae) ) - E.coli (E. coli) - K.pneumoniae (K. pneumoniae) - (+; positive, -; negative) Printed by the Ministry of Economic Affairs Intellectual Property Office Staff Consumer Cooperative [Example 5] Using Ribosomal Protein L7 /L12 Protein Immobilized Affinity Antibody Obtains Specific Reaction with Ribosomal Protein L7/L12 Protein Polyclonal Antibody The Pneumocystis Pneumoniae Paper Size obtained by the method of Example 1 is applicable to China National Standard (CNS) A4 Specification (210X297 mm) -25 - 1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Office Staff Consumer Cooperative Printed V. Description of Invention (23) Ribosomal Protein L7/L12 Protein or Triton X-100 At Qing was on the cell as an antigen use it. About 1 · 2 m of physiological saline containing 1 〇 〇 // g antigen was simultaneously emulsified with 1 · 5 m of Freund's adjuvant. The rabbits were subcutaneously injected with an emulsifier in S P F Japanese white rabbits for immunization. After 5 to 6 immunizations every 2 weeks, the antibody price was determined. The determination of the antibody price is based on the E L I s A method. The Ribosomal Protein L7/L12 protein dissolved in 0. 05% sodium azide PBS was diluted to a concentration of 1 〇//g/2 to 1 0 0 // g After injecting into a 96-well culture plate, adsorption was carried out for 1 night. After the supernatant was removed, a 1% 0% bovine blood albumin solution (in P B S) was added, and the reaction was carried out at room temperature for 1 hour. After removing the supernatant, the product was washed with a washing solution (0 · 0 2 % Tween 20, P B S ). Add 1 〇 〇 // 1 to dilute the normal rabbit blood sputum and immunize the rabbit's anti-blood solution, and react at room temperature for 2 hours. After removing the supernatant liquid, the product is washed with a washing solution. Further, a peroxidase-labeled anti-rabbit I g G antibody solution having a concentration of 50//1 of 50//1 was added, and the mixture was reacted at room temperature for 1 hour. After removing the supernatant liquid, the product was washed again with a washing solution. Each of 1 0 0 // 1 〇 P D solution (manufactured by Sigma) was added, and the mixture was allowed to react at room temperature for 20 minutes. After the coloring, 1 0 0 // 1 1 N sulfuric acid was added and the reaction was stopped. The absorbance at 4 9 2 n m was measured. After confirming that the antibody price has risen, a large amount of blood is collected. After taking blood from the ear artery in a glass centrifuge tube, it was allowed to stand at 37 ° C for 1 hour, and then allowed to stand at 4 ° C for 1 night. Then centrifuge at 3000 rpm for 5 minutes (please read the note on the back of this page first) - Packing and binding - The paper size applies to China National Standard (CNS) A4 specification (210X297 mm) _ 26 - 1282368 A7 B7 V. Description of invention (24), recovery of sputum. Obtain anti-blood stasis and store at 4 °C. An affinity column for the Ribosomal Protein L7/L12 protein of the immobilized P. pyogenes was prepared. The column was activated by Hi Trap NHS (1, manufactured by Phamacia). Immediately after replacing the column with 1 m Μ H C 1 , the Ribosomal Protein L7/L12 protein P B S solution (1 m g /2) was added. After the column was allowed to stand for 30 minutes, the adhesion test was added, and then equilibrated at P B S. After the affinity column was immobilized using the Ribosomal Protein L7/L12 protein of M. pneumoniae, the anti-blood obtained by purifying the sputum of the cells treated with Triton X-100 of M. pneumoniae as an antigen was performed. Polyclonal antibody in sputum. After the anti-blood sputum was diluted 5 times with PBS, the Ribosomal Protein L7/L12 protein was immobilized by the P. oxysporum strain at a flow rate of 0 · 5 / mi η after passing through a filter of 〇······· Column. Thereafter, it was eluted from the column with P i Μ glycine buffer in P Η 2 · 1 and immediately neutralized with ρ Η 9.0 in 1 Μ T ris buffer, by the same antibody valence assay. The ELIS method is used to recover the antibody for the purpose of dissolution. The poly clonal anti-system thus obtained is evaluated by the 〇I A method contained in the special publication No. 7-5 5 95 5 5 . The refined anti-system is used as a collection antibody user of the 〇I A method. Further, as the antibody to be detected, the enzyme marker was used as the peroxidase using the AM C T-1 monoclonal antibody described in Example 4. The enzyme identification is based on the biochemical analysis of the use of wasabi peroxidase (Σ gled VI) combined with the test drug S-acetamidine thioacetate N-pyridyl succinimide (please read the notes on the back π • -- π Write this page) Customs Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperatives Printed Paper Size Applicable to China National Standard (CNS) Α4 Specifications (210X297 mm) -27 - 1282368 A7 _ B7 _ V. Invention Description (25) The method described in 1 3 2 (1 9 8 3 ), 6 8 - 7 3 is carried out. In the 〇IA reaction, the purified polyclonal antibody containing 〇·〇5 % sodium azide PBS was diluted to 10° with 0.10 HEPES buffer ρΗ8·0 on each polyoxynide wafer. After the reaction was carried out at room temperature for 30 minutes, it was washed with distilled water, and coated with a coating liquid containing sucrose and alkali-treated casein. After adding the Triton X-100 at a concentration of 0.5% to each of the microbial culture solutions obtained in the above operation, after extracting at room temperature for 5 minutes, an antigen solution of 15 // 1 was added to the polyfluorene oxide wafer. At room temperature, the reaction was carried out for 10 minutes. Add 1 5 // 1 of 2 0 // g / peroxidase to identify monoclonal antibody and react for 1 〇 minutes. After washing with distilled water, a solution of 1 5 // 1 Τ Μ B (manufactured by K P L) was added, and the mixture was reacted at room temperature for 5 minutes. The product was washed with distilled water, and the cyan color produced by the enzyme reaction was visually observed. As a result, as shown in Table 3, after the purified polyclonal antibody A Ρ Μ Ρ -1 was used as the antibody to be collected, the sensitivity of 1 8 8 /j was clearly displayed to detect the pneumocystis pneumoniae and the inability to detect other microorganisms. Reactive. By immobilizing the affinity column of the Ribosomal Protein L7/L12 protein of P. falciparum, it was confirmed that the polyclonal antibody against P. pneumoniae was obtained. This paper scale applies to China National Standard (CNS) A4 specification (210x297 mm) (please read the note on the back: write this page) Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed 1282368 A7 B7 V. Invention Description (26 Table Results (10 8 cells/mC ) M. pneumoniae (H. pneumoniae) + H. influenzae (E. coli) ATCC10211 - E.coli (E. coli) ATCC25922 - E.faecalis (fecal bacillus) ATCC19433 - K. Pneumoniae (K. pneumoniae) ATCC 1 3 8 8 3 - N. gonorrhoeae (Neisseria gonorrhoeae) IID821 - Nl act amice (N. lactis) ATCC 2 3 970 N. meningitides ATCC13090 - P. Aeruginosa (Pseudomonas aeruginosa) ATCC27853 - GroupB Streptococcus (Group B Streptococcus) ATCC12386 _ S.aureus (Streptococcus mutans) ATCC25923 - S.pneumoniae (Streptococcus pneumoniae) ATCC27336 Which S. pyogenes (Streptococcus pyogenes) ATCC19615 - (Please read the note on the back of this page first) - Installed and edited by the Ministry of Economic Affairs, Intellectual Property Bureau, employee consumption cooperative (+; positive, -; negative) [industrial availability] According to the present invention, when a microorganism is used, an antibody can be specifically detected for an intracellular molecule that is effectively retained, and not only a microorganism of a specific species can be specifically detected, but also all blood-type microorganisms which can detect good precision in the same type. Ribosomal protein, Ribosomal Protemi This paper scale applies to Chinese National Standard (CNS) A4 specification (210X297 mm) -29 - 1282368 A7 B7 V. Description of invention (27) Ribosomal L7/L12 protein antibody After the use of the antibody, the detection of P. pneumoniae with good precision can be performed. Further, when the reagent for detecting microorganisms k i t is used as a component constituting the antibody, it is possible to detect microorganisms having a wider and better precision. (Please read the note on the back: write this page) - Install ·

、1T 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -30 - 1282368 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(28 ) SEQUENCE LISTING <110> ASAHI KASEI KABUSHIKI KAISHA <120>檢測肺炎黴漿菌用抗體 <130〉ASAHI-8 <150〉 JP 2000-062729 <151〉 2000-01-31 <160〉 4 <21〇> 1 <211> 369 <212> DNA <2 1 3> Mycoplasma pneumoniae <400〉 1 atg gca aaa eta gat aaa aac caa tta att gaa teg ttg aag gaa atg 48 Met Ala Lys Leu Asp Lys Asn Gin Leu lie Glu Ser Leu Lys Glu Met 15 10 15 acc ate atg gaa ate gat gaa ate att aag get gta gaa gaa get ttt 96 Thr lie Met Glu lie Asp Glu lie lie Lys Ala Val Glu Glu Ala Phe 20 25 30 gga gta teg gca aca cct gta gta get get ggt get gtt ggl ggt aca 144 Gly Val Ser Ala Thr Pro Val Val Ala Ala Gly Ala Val Gly Gly Thr 35 40 ^ 45 caa gaa get get age gaa gtg act gtg aaa gtt act ggt tac act gac 192 Gin Glu Ala Ala Ser Glu Val Thr Val Lys Val Thr Gly Tyr Thr Asp 50 55 60 本紙張尺度適用中國國家標準(CNS ) A4規格(21 OX297公釐)-31 - (請先閱讀背面之注意事 :寫本頁) -裝· 、11 1282368 A7 B7 五、發明説明(29 ) aac get aaa tta get gig xta aag ett tac ege gaa att get ggt gtt 2401T Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed Paper Standards Applicable to China National Standards (CNS) A4 Specifications (210X297 mm) -30 - 1282368 A7 B7 Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperatives Printing V. Inventions ( 28) SEQUENCE LISTING <110> ASAHI KASEI KABUSHIKI KAISHA <120> Detection of antibodies against M. pneumoniae <130>ASAHI-8 <150> JP 2000-062729 <151> 2000-01-31 <160 〉 4 <21〇> 1 <211> 369 <212> DNA <2 1 3> Mycoplasma pneumoniae <400> 1 atg gca aaa eta gat aaa aac caa tta att gaa teg ttg aag gaa atg 48 Met Ala Lys Leu Asp Lys Asn Gin Leu lie Glu Ser Leu Lys Glu Met 15 10 15 acc ate atg gaa ate gat gaat ate att ag get gta gaa gaa get ttt 96 Thr lie Met Glu lie Asp Glu lie lie Lys Ala Val Glu Glu Ala Phe 20 25 30 gga gta teg gca aca cct gta gta get get ggt get gtt ggl ggt aca 144 Gly Val Ser Ala Thr Pro Val Val Ala Ala Gly Ala Val Gly Gly Thr 35 40 ^ 45 caa gaa get get age gaa gtg act gtg Aaa gtt act ggt tac act gac 192 G In Glu Ala Ala Ser Glu Val Thr Val Lys Val Thr Gly Tyr Thr Asp 50 55 60 This paper scale applies to Chinese National Standard (CNS) A4 specification (21 OX297 mm)-31 - (Please read the note on the back: write This page) - installed · , 11 1282368 A7 B7 5 , invention description (29 ) aac get aaa tta get gig xta aag ett tac ege gaa att get ggt gtt 240

Asn Ala Lys Leu Ala Val Leu Lys Leu Tyr Arg Glu lie Ala Gly Val (請先閱讀背面之注意事寫本頁) 65 70 75 80 g:gt tta atg gaa get aaa act get gtg gaa aaa ett cct tgt gtt gtt 288Asn Ala Lys Leu Ala Val Leu Lys Leu Tyr Arg Glu lie Ala Gly Val (Please read the note on the back first) 65 70 75 80 g:gt tta atg gaa get aaa act get gtg gaa aaa ett cct tgt gtt gtt 288

Gly Leu Met Glu Ala Lys Thr Ala Val Glu Lys Leu Pro Cys Val Val 85 90 95 aag caa gac ate aaa cct gaa gaa get gaa gaa ett aaa aag cgt ttc 336Gly Leu Met Glu Ala Lys Thr Ala Val Glu Lys Leu Pro Cys Val Val 85 90 95 aag caa gac ate aaa cct gaa gaa get gaa gaa ett aaa aag cgt ttc 336

Lys Gin Asp He Lys Pro Glu Glu Ala Glu Glu Leu Lys Lys Arg Phe 100 105 110 gtt gaa gtt gga gca act gtt gaa ate aaa taa 369Lys Gin Asp He Lys Pro Glu Glu Ala Glu Glu Leu Lys Lys Arg Phe 100 105 110 gtt gaa gtt gga gca act gtt gaa ate aaa taa 369

Val Glu Val Gly Ala Thr Val Glu He Lys 115 120Val Glu Val Gly Ala Thr Val Glu He Lys 115 120

<210〉 2 <211> 122 <212> PRT 經濟部智慧財產局員工消費合作社印製 <2 1 3> Mycoplasma pneumoniae <400> 2 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)-32 - 經濟部智慧財產局員工消費合作社印製 1282368 五、發明説明(30 Μβτ Ala Lys Leu Asp Lys Asn Gin Leu lie Glu Ser Leu Lys Glu Met 1 5 10 15<210〉 2 <211> 122 <212> PRT Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Print <2 1 3> Mycoplasma pneumoniae <400> 2 This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm)-32 - Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printed 1282368 V. Invention description (30 Μβτ Ala Lys Leu Asp Lys Asn Gin Leu lie Glu Ser Leu Lys Glu Met 1 5 10 15

Thr He Met Glu lie Asp Glu lie lie Lys Ala Val Glu Glu Ala Pbe 20 25 30Thr He Met Glu lie Asp Glu lie lie Lys Ala Val Glu Glu Ala Pbe 20 25 30

Gly Val Ser Ala Thr Pro Val Val Ala Ala Gly Ala Val Gly Gly Thr 35 40 45Gly Val Ser Ala Thr Pro Val Val Ala Ala Gly Ala Val Gly Gly Thr 35 40 45

Gin Glu Ala Ala Ser Glu Val Thr Val Lys Val Thr Gly Tyr Thr Asp 50 55 60Gin Glu Ala Ala Ser Glu Val Thr Val Lys Val Thr Gly Tyr Thr Asp 50 55 60

Asn Ala Lys Leu Ala Val Leu Lys Leu Tyr Arg Glu II© Ala Gly Val 65 70 75 80Asn Ala Lys Leu Ala Val Leu Lys Leu Tyr Arg Glu II© Ala Gly Val 65 70 75 80

Gly Leu \lei Glu Ala Lys Thr Ala Val Glu Lys Leu Pro Cys Val Val 85 90 95Gly Leu \lei Glu Ala Lys Thr Ala Val Glu Lys Leu Pro Cys Val Val 85 90 95

Lys Gin Asp lie Ly^ Pro Glu Glu Ala Glu Glu Leu Lys Ly$ Arg Phe 100 105 110Lys Gin Asp lie Ly^ Pro Glu Glu Ala Glu Glu Leu Lys Ly$ Arg Phe 100 105 110

Val Glu Val Gly Ala Thr Val Glu lie Lys 115 120 <210〉 3Val Glu Val Gly Ala Thr Val Glu lie Lys 115 120 <210〉 3

<211> 29 <212> DNA <213〉Artificial Seq uence <220> <223〉自 Mycoplasma pneumoniae 取得 Ribosomal Protein L7/L12基因使用之pcR引子DNA。 <400〉 3 aatggatcca tggcaaaact agataaaaa 29 , 本紙張尺度適用中國國家標準(CNS ) A4規格(21 OX 297公釐)-33 -<211> 29 <212> DNA <213> Artificial Seq uence <220><223> The pcR primer DNA used for the Ribosomal Protein L7/L12 gene was obtained from Mycoplasma pneumoniae. <400〉 3 aatggatcca tggcaaaact agataaaaa 29 , This paper scale applies to Chinese National Standard (CNS) A4 specification (21 OX 297 mm)-33 -

1 -- I 1 - · 1282368 A7 B7 五、發明説明(31 )1 -- I 1 - · 1282368 A7 B7 V. Description of invention (31 )

<210> 4 <211> 30 <212〉DNA <2 1 3> Artificial Sequence <220> <223> 自 Mycoplasma pneumoniae 耳又得 Ribosomal Protein L7/L12基因使用之P C R引子DNA。 <400〉 4<210> 4 <211> 30 <212>DNA<2 1 3> Artificial Sequence <220><223> From Mycoplasma pneumoniae, the P C R primer DNA used for the Ribosomal Protein L7/L12 gene was obtained. <400〉 4

QA tgactcgagt tatttgatxt caacagttgc (請先閱讀背面之注意事 :寫本頁) -裝-QA tgactcgagt tatttgatxt caacagttgc (please read the note on the back: write this page) - install -

、1T 線_ 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) _ 34 -, 1T line _ Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printing This paper scale applies China National Standard (CNS) A4 specification (210X297 mm) _ 34 -

Claims (1)

[282368 1公告4| L —^ 六、申請專利範圍[282368 1 Announcement 4| L —^ VI. Application for patent scope 专 ϊΐ. 第90 1 0 1 940號專利申請案 中文申請專利範圍修正本 (請先閲讀背面之注意事項再填寫本頁) 民國95年6月7日修正 1 · 一種抗體,其係對肺炎黴發菌(Mycoplasma pneumoniae )屬微生物的 Ribosomal Protein(核糖體) L7/L12爲特異性反應之抗體,其特徵爲與肺炎黴漿菌( Mycoplasma pneumoniae )之 Rib osomal Protein L7/L12 會 反應’但與其他種或屬的微生物之 Ribosomal Protein L7/L12不會反應者。 2 .如申請專利範圍第1項之抗體,其中該抗體係與 酵素結合之抗體者。 3 · —種肺炎黴漿菌屬微生物之檢測方法,其特徵係 利用如申請專利範圍第1項或第2項中任一項之抗體。 經濟部智慧財產局員工消費合作社印製 4 · 一種檢測方法,其特徵係由a )使檢體與溶解液 接觸後由微生物萃取出核糖核蛋白體蛋白質、b )將經萃 取之檢體與如申請專利範圍第1項或第2項中任一項之抗 體固定於固體表面之收集抗體接觸後,於核糖核蛋白體蛋 白質與收集抗體間形成抗原抗體複合體者、以及c )利用 如申請專利範圍第1項或第2項中任一項之抗體作爲檢測 用抗體’檢測出檢測抗原抗體複合體所成之檢測檢體中肺 炎黴漿菌屬微生物者。 5 ·如申請專利範圍第4項之方法,其中該檢測用抗 體係與酵素結合之抗體者,其抗原抗體複合體係藉由該酵 素之特異性基質所檢測者。 本紙張尺度適用中國國家標準(CNS) A4規格(21〇X:297公釐) -1 - 1282368 A8 B8 C8 D8 六、申請專利範圍 6 · —種檢測肺炎黴漿菌屬微生物之檢測用試藥_ ^ (kit),其特徵係利用如申請專利範圍第1項或第2 項之抗體者。 7 · —種如申請專利範圍第1項之抗體製造方法,其 特徵爲該方法係以基因操作方法或由微生物分離純化後取 得之肺炎黴漿菌屬微生物之Ribosomal ProteinL7/L12蛋白 質’其部份肽,或相當於其部份肽之合成肽做爲免疫源 者0 li k— n 0—t n n n I — - n (請先閲讀背面之注意事項再填寫本頁) 訂Special Issue. Patent Application No. 90 1 0 1 940 Patent Application Amendment (please read the note on the back and then fill out this page) Amendment of June 7, 1995 1 · An antibody against Pneumonia Mycoplasma pneumoniae is a microbial Ribosomal Protein L7/L12 is a specific antibody that is characterized by the reaction with Rib osomal Protein L7/L12 of Mycoplasma pneumoniae' but with other Ribosomal Protein L7/L12 of the species or genus of microorganisms does not respond. 2. The antibody of claim 1, wherein the antibody is bound to an antibody to the enzyme. A method for detecting a microorganism of the genus Pneumocystis, which is characterized by the use of an antibody according to any one of claims 1 to 2. Ministry of Economic Affairs, Intellectual Property Bureau, Staff Consumer Cooperatives, Printing 4 · A detection method characterized by a) extracting ribonucleoprotein from microbes after contacting the sample with the solution, b) extracting the sample with The antibody of any one of claim 1 or 2, wherein the antibody is immobilized on a solid surface, and the antigen-antibody complex is formed between the ribonucleoprotein protein and the collected antibody, and c) The antibody according to any one of the first or the second aspect, wherein the antibody for detection is detected as a microorganism of the genus Pneumocystis in the test sample obtained by detecting the antigen-antibody complex. 5. The method of claim 4, wherein the antigen-antibody complex system is detected by a specific substrate of the enzyme. This paper scale applies to China National Standard (CNS) A4 specification (21〇X: 297 mm) -1 - 1282368 A8 B8 C8 D8 VI. Patent application scope 6 · Test for the detection of microorganisms of the genus Pneumocystis _ ^ (kit), which is characterized by the use of antibodies as in claim 1 or 2 of the patent application. 7. The method for producing an antibody according to the first aspect of the patent application, characterized in that the method is a part of the Ribosomal Protein L7/L12 protein of the microorganism belonging to the genus Pneumocystis obtained by genetic manipulation or purification and purification by microorganisms. Peptide, or synthetic peptide equivalent to its partial peptide as the source of immunity 0 li k— n 0—tnnn I — - n (Please read the notes on the back and fill out this page) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家禚準(CNS ) A4規格(210X297公釐) -2 -Printed by the Intellectual Property Office of the Ministry of Economic Affairs, the Consumer Cooperatives. This paper scale applies to the Chinese National Standard (CNS) A4 specification (210X297 mm) -2 -
TW090101940A 2000-01-31 2001-01-31 Antibody for detecting mycoplasma pneumoniae TWI282368B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000062729 2000-01-31

Publications (1)

Publication Number Publication Date
TWI282368B true TWI282368B (en) 2007-06-11

Family

ID=18582698

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090101940A TWI282368B (en) 2000-01-31 2001-01-31 Antibody for detecting mycoplasma pneumoniae

Country Status (7)

Country Link
JP (2) JP5331285B2 (en)
KR (1) KR100734995B1 (en)
CN (1) CN100516210C (en)
AU (1) AU2001230532A1 (en)
CA (1) CA2398469C (en)
TW (1) TWI282368B (en)
WO (1) WO2001057199A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004201605A (en) * 2002-12-26 2004-07-22 Asahi Kasei Corp Dna encoding ribosome l7/l12 protein of bacterium of genus legionella
KR100905066B1 (en) * 2007-12-04 2009-06-30 주식회사 바이오랜드 The recombinant proteins for the diagnosis of diseases infected from Mycoplasma pneumoniae and the diagnostic kits comprising the same
JP5458344B2 (en) * 2008-01-30 2014-04-02 旭化成株式会社 Antibody immobilization carrier
JP5712140B2 (en) * 2009-12-04 2015-05-07 株式会社Lsiメディエンス Method for detecting microorganisms belonging to Mycoplasma pneumoniae and / or Mycoplasma genitalium
JP6150559B2 (en) * 2013-02-28 2017-06-21 旭化成株式会社 Detection method of Mycoplasma pneumonia
US10174103B2 (en) 2013-08-23 2019-01-08 Tauns Co., Ltd. Mycoplasma pneumoniae immunological detection method and kit
JP2016031353A (en) 2014-07-30 2016-03-07 株式会社 富山研究所 Mycoplasma pneumoniae detection reagent and use therefor
JP7402659B2 (en) * 2019-11-01 2023-12-21 旭化成株式会社 Antibodies for detecting Mycoplasma pneumoniae in a specimen, and methods, reagents, and kits for detecting Mycoplasma pneumoniae using such antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7068587A (en) * 1986-03-27 1987-10-01 Cetus Corporation Monoclonal antibody immunoblot assay for antigens
JP3592709B2 (en) * 1990-09-11 2004-11-24 インスティテュート・フォー・チャイルド・ヘルス・リサーチ Cloning and sequencing of dermatophagoides allergens
AU3355095A (en) * 1994-09-02 1996-03-27 Meiji Milk Products Company Limited Diagnostic drug for chlamydia infection
JPH0931097A (en) * 1995-07-24 1997-02-04 Yuka Medeiasu:Kk Determination of chlamydia trachomatis antibody

Also Published As

Publication number Publication date
JP5331285B2 (en) 2013-10-30
CA2398469A1 (en) 2001-08-09
JP2012006968A (en) 2012-01-12
KR100734995B1 (en) 2007-07-04
KR20020073192A (en) 2002-09-19
AU2001230532A1 (en) 2001-08-14
WO2001057199A1 (en) 2001-08-09
CN1406279A (en) 2003-03-26
CN100516210C (en) 2009-07-22
CA2398469C (en) 2009-04-21

Similar Documents

Publication Publication Date Title
JP5219057B2 (en) Antibodies for detecting microorganisms
JP6688767B2 (en) Compositions and methods for detecting antibodies specific for Anaplasma phagocytofilm (Aph) and Anaplasma platys (Apl)
JP2012006968A (en) Antibody for detecting mycoplasma pneumoniae
US9910037B2 (en) Conjugation of multiple vancomycin molecules on a polyvinyl alcohol backbone for the capture of microorganisms
JP5712140B2 (en) Method for detecting microorganisms belonging to Mycoplasma pneumoniae and / or Mycoplasma genitalium
JP2015071607A (en) Methods and compositions for detection of ehrlichia chaffeensis (vlpt)
JP2008507544A (en) Concentrated antibody for detecting mycobacterial infection, method of use, and diagnostic test using the same
US20090269789A1 (en) Antibodies for detecting microorganisms
JPS63159762A (en) Method of evaluating mouth microbe
JP2012017334A (en) Antibody for detecting chlamydia pneumoniae
US20080124747A1 (en) Methods for detecting b. anthracis infection
JPH08502720A (en) Methods and compositions for the diagnosis of cat scratch disease and bacterial hemangiomatosis
BRPI0816437B1 (en) purified polypeptides and methods for detecting ehrlichia chaffeensis in a test sample
US20020012668A1 (en) DNA sequence encoding the specific and antigenic outer membrane protein of salmonella typhi
JPH10218895A (en) Modified protein, dna capable of coding for the same, recombinant vector containing the same dna, transformant containing the same recombinant vector, production of modified protein, measurement and measuring reagent for anti-triponema pallidum antibody, diagnostic agent for infection with syphilis and production of antitreponema pallidum antibody
JP2004154075A (en) New analyzing method
JP5829467B2 (en) Examination method of pathological condition caused by Legionella
JP2001286295A (en) Antibody for detecting chlamydia trachomatis
George Immunodiagnostic system for neurotuberculosis-suited to laboratories in developing countries.
JPH09288107A (en) Preparation of chlamydia-pneumoniae antigen

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent